Stockwinners Market Radar for May 19, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:01 EDT Quhuo receives Nasdaq notification regarding late 20-F filing - Quhuo Limited announced that it received a notification letter dated May 18, 2022 from the Listing Qualifications Department of The Nasdaq Stock Market Inc., indicating that the Company is no longer in compliance with the Nasdaq Listing Rules since the Company has not yet filed its annual report on Form 20-F for the fiscal year ended December 31, 2021. Nasdaq Listing Rule 5250(c)(1) requires Nasdaq-listed companies to timely file all periodic reports. This Notification Letter has no immediate effect on the listing of the company's American depositary shares on the Nasdaq Global Market. Pursuant to the Nasdaq Listing Rules, the company has 60 calendar days from the date of the Notification Letter to submit a plan to regain compliance with Nasdaq Listing Rules. If Nasdaq accepts the Compliance Plan, it may grant the company an extension until November 14, 2022 to regain compliance. The company experts either to file its 2021 Form 20-F or submit the Compliance Plan within the prescribed 60-day period.

18:59 EDT Mosaic raises quarterly dividend to 15c from 11.25c per share - The dividend will be paid on June 16, 2022, to stockholders of record as of the close of business on June 2, 2022.

18:40 EDT Atkore acquires Talon Products, terms not disclosed - Atkore "announced the acquisition of the assets of Talon Products, LLC, a provider of patented, non-metallic, injection molded cable cleats for use in power distribution applications. Sold as Talon Cable Cleats, the product supports and holds electrical cables when installed at intervals along the length of cable. Talon Products is a small business headquartered in Hammond, Louisiana and will continue operating at its current location. Terms of the sale are undisclosed."

18:03 EDT Maxeon Solar appoints Philippe Costemale as new COO - Maxeon Solar appointed Philippe Costemale as its new COO. Philippe Costemale will succeed Markus Sickmoeller, who will leave the company in September following an orderly transition of duties. Philippe Costemale was most recently VP Global Manufacturing and Supply Chain for Technicolor based in Hong Kong. Before, he spent around 14 years at Jabil where, as GM for Europe, he led the business and operations. Costemale will be joining the Maxeon team at its Singapore Headquarters.

17:51 EDT Glass Lewis urges American Vanguard investors to vote for Cruiser nominees - Cruiser Capital Master Fund LP and its affiliates, a top ten shareholder of American Vanguard Corporation, owning approximately 2.5% of AVD's outstanding shares, announced that leading proxy advisory firm Glass, Lewis & Co. has recommended that stockholders vote for ALL of Cruiser's three director candidates by voting on the BLUE proxy card at the June 1, 2022, Annual Meeting of Stockholders. In its report, Glass Lewis writes that, "(W)e believe CCA (Cruiser Capital Advisors) has ultimately presented investors with a compelling case for change, and has nominated individuals well suited to addressing what appear to be AVD's most significant operational and governance failings."

17:50 EDT SWK Holdings announces $10M share repurchase plan - SWK announced that its Board of Directors has authorized the company to repurchase up to an aggregate of $10M of the company's common stock from time-to-time until May 15, 2023, through a "10b5-1 trading plan" in compliance with Rule 10b-18 under the Securities Exchange Act of 1934.

17:35 EDT Middleby authorizes buyback of up to 2.5M additional shares - According to a regulatory filing, on May 16, 2022, The Middleby Corporation's board of directors authorized the repurchase of up to an additional 2,500,000 shares of the company's common stock under the company's existing share repurchase program. As previously reported, in November 2017, the board of directors of the company authorized the repurchase in the aggregate of up to 2,500,000 shares of the company's common stock under the Repurchase Program. As of April 2, 2022, 2,027,577 shares had been purchased under the Repurchase Program and 472,423 shares remained authorized for repurchase.

17:09 EDT Radius Health announces publication of elacestrant clinical trial data - The Menarini Group and Radius Health "announce that data from the pivotal phase 3 EMERALD clinical trial evaluating elacestrant as a monotherapy vs. standard of care for the treatment of ER+/HER2- advanced or metastatic breast cancer were published in the Journal of Clinical Oncology. Elacestrant is the first oral selective estrogen receptor degrader demonstrating a significant improvement in PFS vs. SOC with manageable safety in a phase 3 trial for patients with ER-positive/HER2-negative advanced breast cancer. Among the 477 patients enrolled in the trial, 239 received elacestrant. Of the 165 patients who received fulvestrant, all were pretreated with AI during the treatment for metastatic disease except n=6 who received fulvestrant. Of the 73 who received AI, all were pretreated with fulvestrant except n=4. Primary endpoints were PFS by blinded independent central review (IRC) in all patients and patients with detectable ESR1 mutations. Elacestrant significantly reduced the risk of disease progression or death by 30% in all patients and by 45% in patients with ESR1 mutation."

17:03 EDT SolarEdge, Huawei sign global patent license agreement, end patent litigation - SolarEdge Technologies and Huawei Technologies have agreed on a global patent license agreement between the two companies. The agreement includes a cross license that covers patents relating to both companies' products, and grants certain other rights. In addition, the agreement will result in a settlement of all pending patent-litigation between the companies. The specific terms of the agreement are confidential. This agreement ends lawsuits between the companies that were pending in Germany and China.

17:01 EDT Myers Industries CFO Sonal Robinson to step down - Myers Industries "announced the upcoming departure of Sonal Robinson, Executive Vice President andCFO. Ms. Robinson joined the company in February 2021, was appointed CFO effective March 15, 2021, and has resigned to pursue other opportunities. To support a smooth transition, Ms. Robinson will continue in her role at Myers until July 1, 2022. Monica Vinay, Vice President, Investor Relations and Treasurer, has been named Interim CFO and will assume that role upon Ms. Robinson's departure. The company has launched a formal search process to identify a permanent successor."

16:39 EDT ChromaDex to establish Tru Niagen JV in China with three other companies - ChromaDex announced it has entered into an agreement to establish a joint venture, or JV, through its wholly owned subsidiary ChromaDex Asia. Upon establishment of the JV, membership of ChromaDex Asia will collectively consist of the company; Crystal Lake Developments ; Pioneer Idea and Hong Kong Taikuk. ChromaDex Asia is expected to assume the distribution agreement noted in a previous announced press release with Sinopharm Xingsha as it relates to the commercialization of Tru Niagen in mainland China and its territories, excluding Hong Kong, Macau and Taiwan. The JV's entry into a distribution agreement will be contingent upon Sinopharm successfully attaining health food product registration for Tru Niagen with the People's Republic of China's State Administration for Market Regulation, or SAMR. SAMR is the regulatory body responsible for health food registration. Health food registration is a key regulatory step required to be able to broadly market and distribute Tru Niagen products in China. Formation of the joint venture is subject to customary closing conditions.

16:35 EDT Kadant authorizes share repurchase for up to $50M - Kadant has authorized the repurchase of up to $50M of its equity securities effective May 19, 2022 through May 19, 2023. The company has not repurchased any shares of its common stock under the $20M authorization that will expire on May 20, 2022.

16:31 EDT Granite secures $10M contract for I-40 work in California - Granite "announced that it has secured the contract for Segment Five of the I-40 Median Fill PM 100-125 in San Bernardino County, California. The approximately $10M contract was awarded by Caltrans and will be funded by a mixture of state and federal sources. The award is anticipated to be included in Granite's second quarter CAP."

16:28 EDT Lordstown Motors names Daniel Ninivaggi as Chairman of the Board - Lordstown Motors announced that at its annual meeting of stockholders, Joseph B. Anderson, Jr., Laura J. Soave and Angela Strand were elected as independent directors. Anderson and Soave are new directors, and each has extensive experience in the global automotive industry. Incumbent director Strand is joining the Compensation Committee, Anderson will serve as a member of the Audit Committee and Soave will serve on the Nominating and Corporate Governance Committee of the Board of Directors. The Board of Directors has also combined the roles of Chairman of the Board and CEO and current CEO, Daniel Ninivaggi, will serve in this capacity, effective following the annual meeting. David Hamamoto, a current independent director and Chairman of the Nominating and Corporate Governance Committee of the Board, will serve as lead independent director, also effective following the annual meeting.

16:26 EDT Covenant Logistics promotes James Grant to CFO - The company promoted James Grant to executive VP and CFO and Joey Ballard to executive VP, people and safety. The company said, "Since joining the company in 2019, Grant has proven that he has the financial and strategic skills to excel as our Chief Financial Officer."

16:23 EDT Covenant Logistics announces $75M share repurchase plan, real estate sale - Covenant Logistics Group's board of directors approved a new stock repurchase authorization of up to $75M following the recent completion of the previously announced $30M 10b5-1 repurchase plan. The company also agreed to sell a California terminal. The transaction is expected to close within 60 days, subject to customary conditions. The company expects to record a pretax gain on sale of property of approximately $45M. The company said, "We expect to relocate personnel and equipment to other locations and lower our operating expenses associated with Southern California by approximately $500,000 annually with no disruption in service."

16:22 EDT CooTek Cayman Inc (Class A ADS) trading halted, news pending

16:20 EDT Foghorn Therapeutics trading resumes

16:19 EDT Natuzzi board approves proposal to approve new stock option plan - Natuzzi announced that its Board of Directors has approved a proposal to be submitted to the company's shareholders at an extraordinary shareholders' meeting of the company to be convened in the near future to approve the terms and conditions of a new stock option plan for the Group's personnel and authorize the Board to carry out, in one or more tranches, the capital increase without preemptive rights that will be necessary to issue ordinary shares of the company to employees under the Plan. The Plan provides for the grant of stock options to certain employees and directors of the company and its affiliates during the 2022-2026 period, which would vest and become exercisable subject to the continuation of the relevant working relationship and/or the achievement of performance targets as determined by the Board, which is also entitled under the Plan to determine that the stock options would vest and become exercisable only subject to the continuation of the relevant working relationship.

16:18 EDT Chubb announces new $2.5B share repurchase program - The Board also announced authorization of a new share repurchase program of up to $2.5B through June 30, 2023. The company's existing share repurchase authorization will remain effective through June 30, 2022 and, while effective, would be used before the share repurchase program authorized May 19.

16:17 EDT Chubb raises annual dividend 3.75% to $3.32 per share - Chubb announced that at its 2022 Annual General Meeting, held at the company's offices in Zurich, Switzerland, shareholders approved a 3.75% increase in the company's dividend to $3.32 per share annually 83c per share, per quarter, from $3.20 per share, or 80c per share, per quarter. This marks the twenty-ninth consecutive annual increase in the company's dividend. The company's Board of Directors declared that shareholders of record at the close of business on June 17, will be entitled to payment of the first installment of 83c per share on July 8.

16:16 EDT Foghorn Therapeutics announces FHD-286 study placed on clinical hold by FDA - Foghorn Therapeutics announced the FDA has placed the Phase 1 dose escalation study of FHD-286 in relapsed and/or refractory acute myelogenous leukemia, or AML, and myelodysplastic syndrome, or MDS, on a partial clinical hold. The partial clinical hold was initiated by the FDA following the report of a recent death that occurred in a subject with potential differentiation syndrome. Differentiation syndrome is associated with AML/MDS therapeutics that induce differentiation, an effect that is believed to be on-target for the proposed mechanism of action for FHD-286. The FDA has requested a review of the safety database, risk mitigation strategies and a breakdown of clinical activity across dose levels. Patients currently enrolled in the dose escalation Phase 1 study of FHD-286 in AML/MDS and benefitting from treatment may continue to receive treatment, although no new patients can be enrolled until the partial clinical hold is resolved. The partial clinical hold does not apply to the FHD-286 dose escalation Phase 1 study in metastatic uveal melanoma, or mUM, with enrollment in that study continuing per protocol. "Patient safety remains our top priority. We appreciate the dialogue with the FDA and will work diligently with the Agency to resolve the partial clinical hold in AML/MDS as soon as possible," said Foghorn CEO Adrian Gottschalk. Until Foghorn has resolved the partial clinical hold for the AML/MDS study, the company is suspending guidance on the timing of the data release for the dose escalation phase of the FHD-286 program.

16:16 EDT CPI Aerostructures trading halted, news pending

16:15 EDT LCI Industries authorizes $200M stock repurchase program - LCI Industries announced that its Board of Directors has authorized a new $200M stock repurchase program over the next three years. "This repurchase program demonstrates the Board of Directors' and senior management's commitment to deploying capital that will create value for shareholders, underscoring our confidence in LCI's long-term growth objectives. Our strong operating cash flows, balance sheet, and borrowing capacity give us the flexibility to return capital to shareholders while making further investments in our business to drive growth and innovation, pursue strategic acquisitions, and maintain appropriate debt levels," said Jason Lippert, LCI Industries' President and Chief Executive Officer.

16:12 EDT Deckers Brands announces leadership transition in Performance Lifestyle - Deckers Brands announced that after seven years leading the HOKA and Teva brands to new heights Wendy Yang is stepping down from her role as President of Performance Lifestyle, effective as of the end of the month. Stefano Caroti, President of Omni-Channel and a 30-year industry veteran, will assume Yang's responsibilities on an interim basis while the company conducts a leadership search. Yang will remain with the company in a consulting role through August 15, to ensure a smooth transition.

16:11 EDT Kinetik Holdings announces two-for-one stock split in form of dividend - Kinetik Holdings announced that the board of directors has approved and declared a two-for-one split of the company's common stock in the form of a stock dividend. The company anticipates that the stock split will increase liquidity in the trading of the company's stock and will make its stock more accessible to its employees and investors. The stock split will be accomplished by distributing one additional share of Class A common stock for each share of Class A common stock outstanding and one additional share of Class C common stock for each share of Class C common stock outstanding. The additional shares of common stock will be issued on Wednesday, June 8 to holders of record as of the close of business on Tuesday, May 31. Trading of the Class A common stock will begin on a stock split-adjusted basis on Thursday, June 9. After giving effect to the stock split, Kinetik expects to have in total approximately 135M shares of common stock outstanding. Beginning with the second quarter 2022 dividend, the quarterly dividend on the company's common Stock will be 75c per share.

16:08 EDT Highwoods Properties sells FBI Tampa Field Office for $70.4M - Highwoods Properties has sold the FBI Tampa Field Office, a 138,000 square foot office building developed by Highwoods as a build-to-suit for the FBI in 2005 and renewed under a long-term lease in 2020, for $70.4M. The company also expects to close on the sale of its last remaining office buildings in Greensboro, which total 299,000 square feet and are 88.2% occupied, later this quarter or early in the third quarter for $20.3M. In 2022, these office buildings were projected to generate $6.3M of annual GAAP net operating income and $5.7M of annual cash net operating income, which includes the impact of free rent. The company has also sold an 8.9-acre non-core land parcel adjacent to its One Independence office building in Tampa's Westshore BBD for $6.9M to a developer who plans to construct apartment units. The company expects to record $2.3M of land sale gains in the second quarter.

16:07 EDT Foghorn reports FDA placed Phase 1 dose escalation study of FHD-286 on hold

16:06 EDT QCR Holdings announces 1.5M share stock repurchase plan - QCR Holdings announced that its board of directors authorized a share repurchase program, permitting the repurchase of up to 1.5M shares of its outstanding common stock, or approximately 8.5% of the outstanding shares as of May 1.

16:05 EDT Atara provides update on Bayer collaboration - Atara Biotherapeutics, Inc. (ATRA) announced that it received notification of Bayer's (BAYRY) intention to end the exclusive worldwide licensing agreement for next-generation mesothelin-directed CAR T-cell therapies. The collaboration included the funding and development of ATA3271, an armored allogeneic T-cell immunotherapy, and an autologous version, ATA2271, for high mesothelin-expressing tumors such as malignant pleural mesothelioma and non-small-cell lung cancer. Both ATA2271 and ATA3271 incorporate Atara's novel inclusion of armoring in the form of a PD-1 DNR construct to overcome checkpoint inhibition and a 1XX costimulatory domain on the CAR to enhance expansion and functional persistence of the CAR T-cells. ATA3271 leverages Atara's EBV T-cell platform and is currently in IND-enabling studies. "We acknowledge Bayer's decision to end our collaboration following Bayer's strategic review and asset-level prioritization of its pipeline, including cell and gene therapy," said Jakob Dupont, M.D., Head of Global Research & Development at Atara. "Based on the clinical and pre-clinical data generated to date, we remain confident in the potential of ATA2271 and ATA3271 to address patient need in solid tumors and are re-assessing our strategy on how best to generate value from the programs moving forward." Upon termination of the agreement in September 2022, the rights and licenses granted by Atara to Bayer under the collaboration will be returned to Atara, and Atara will have full rights to continue the clinical development and future commercialization of its programs worldwide. Atara will continue to support the ongoing ATA2271 Phase 1 study, which is being conducted by Memorial Sloan Kettering Cancer Center who has voluntarily paused enrollment of new patients in the study on a temporary basis. Atara and MSK expect to provide a Phase 1 data update for ATA2271 in H2 2022. Atara will also continue to lead IND-enabling studies and process development for ATA3271.

16:00 EDT General Dynamics announces award modification with total value of $313.9M - General Dynamics Electric Boat, a business unit of General Dynamics, announced it was awarded a modification to the previously awarded Columbia Integrated Product and Process Contract by the Naval Sea Systems Command. The modification has a total value of $313.9M. The contract modification will support submarine industrial base development and expansion for the construction of the Columbia-class fleet ballistic missile submarines as well as additional support for the manufacturing, procurement and delivery efforts for United Kingdom Strategic Weapon Support System kits.

15:03 EDT Exxon Mobil to sell Barnett Shale assets to BKV for $750M - ExxonMobil said it signed an agreement with subsidiaries of BKV Corporation for the sale of operated and non-operated Barnett Shale gas assets in Texas for $750M with additional payments contingent on future natural gas prices. ExxonMobil removed the Barnett Shale gas assets operated by its subsidiaries XTO Energy and Barnett Gathering from its development plan in 2020. As part of the agreement, all employees with ExxonMobil subsidiaries in the Barnett Shale will receive full employment offers with BKV. The sale is expected to close in the second quarter of 2022.

14:20 EDT Hasbro names Najuma Atkinson chief people officer - Hasbro announced that Najuma Atkinson has been appointed Chief People Officer. She assumes this position following the previously disclosed retirement of Dolph Johnson, Global Chief Human Resources Officer, after more than two decades of service at Hasbro. In her new position, Ms. Atkinson will lead Hasbro's global Human Resources organization, building a people and culture strategy that attracts and retains top talent, supporting the acceleration of Hasbro's brand blueprint. "Naj has already been a terrific addition to our team with her global HR experience, digital-first mindset, and deep expertise developing talent, and I'm thrilled to continue working with her as Chief People Officer," said Chris Cocks, Chief Executive Officer, Hasbro. "She understands the capabilities and new technologies needed to recruit top talent to execute the Hasbro gameplan and position us for future success."

13:53 EDT Allegiant Travel reports preliminary April traffic up 21.6% vs. 2019 - Reports April ASMs up 15.5% vs. 2019. Passengers were up 19.5% vs. 2019 to 1.52M.

13:34 EDT Lear acquires Thagora Technology, terms not disclosed - Lear Corporation announced it has acquired Thagora Technology SRL, a privately held company specializing in material utilization hardware and software technologies based in Iasi, Romania. The company said, "Thagora's proprietary solutions will complement Lear's sustainable manufacturing processes by reducing scrap and lowering energy usage during production. In addition, Thagora's Industry 4.0 technology brings significant advances to manufacturing operations through engineering and logistics, including improved material traceability, and facility footprint utilization."

13:31 EDT Ohio Valley Banc Corp appoints Larry Miller as CEO - Thomas Wiseman, chairman of the board of Ohio Valley Bank and Ohio Valley Banc, announced the promotion of Larry Miller, II, to the position of CEO of both Ohio Valley Bank and OVBC. As president and CEO, Miller will be responsible for all business units in the company and its subsidiaries. Wiseman, who previously served as CEO, will remain as chairman. Ryan Jones was promoted to COO of both Ohio Valley Bank and OVBC. Jones will continue to hold the title of risk officer in both Ohio Valley Bank and OVBC as well. In these roles, Jones will oversee the company's enterprise risk management efforts while also managing the company's operational units.

12:20 EDT MeMD unveils name change to Walmart Health Virtual Care - MeMD, a multi-specialty national telehealth provider, announced its name change to Walmart Health Virtual Care as part of its official transition to the Walmart Health family. The name change marks the final stages of MeMD's acquisition by Walmart Health, which was initially announced in May 2021, the company said in a statement. "In this next evolution of MeMD, we are excited to begin officially delivering services as Walmart Health Virtual Care, bringing affordable, high-quality telehealth options to as many organizations as possible," said Bill Goodwin, head of Walmart Health Virtual Care. "This is also a win for our current patients and employers who will have access to a wide range of additional health offerings under the Walmart Health umbrella."

12:02 EDT CD Projekt says next-gen 'Witcher 3' version to release in 4Q22 - CD Projekt (OTGLY) said that the next-generation version of "The Witcher 3: Wild Hunt" for Xbox Series X/S (MSFT) and PlayStation 5 (SONY) is planned for release in 4Q22. The Fly notes that this release window has been delayed several times. Reference Link

12:00 EDT Direxion Daily Junior Gold Miners Index Bear 3x Shares falls -12.9% - Direxion Daily Junior Gold Miners Index Bear 3x Shares is down -12.9%, or -$1.48 to $9.95.

12:00 EDT Shopify rises 14.2% - Shopify is up 14.2%, or $51.20 to $411.82.

12:00 EDT Bill.com rises 16.6% - Bill.com is up 16.6%, or $16.92 to $118.55.

11:20 EDT Take-Two, Zynga stockholders approve proposals related to pending transaction - Take-Two Interactive Software (TTWO) and Zynga (ZNGA) announced that the stockholders of each organization have approved all proposals related to Take-Two's combination with Zynga at each company's respective Special Meeting of Stockholders. As a result, the closing of the business combination is expected to occur on May 23, 2022 before market open, subject to the satisfaction of the remaining customary closing conditions. Shares of Zynga will cease trading after the market close on May 20, 2022, and following the closing, Zynga will no longer be listed on the NASDAQ exchange. Under the terms of the merger agreement, upon the closing of the transaction, Zynga will be combined with Take-Two on the terms set forth in the merger agreement and Zynga stockholders will be entitled to receive $3.50 in cash and 0.0406 shares of Take-Two common stock per share of Zynga common stock.

11:04 EDT Could crypto crash be good for U.S. economy? Probably. - Find out why the dramatic decline in cryptocurrencies may be good for the U.S. economy in this quick video by The Fly's partners at InvestingChannel. Reference Link

11:01 EDT ADM appoints Ron Bandler as treasurer - ADM has appointed Ron Bandler Vice President and Treasurer. He succeeds John Stott, who recently took on a new role as President, ADM Investor Services. Bandler previously served as Assistant Treasurer where he was responsible for foreign exchange risk management, debt capital markets, equity capital markets, cash management, accounts payable, bank relationships, revolving credit facilities and rating agency relationships.

10:48 EDT Frontier Group supports Spirit in urging shareholders to reject JetBlue tender - Frontier Group Holdings (ULCC) commented on Spirit Airlines' (SAVE) announcement that it is urging shareholders to reject JetBlue Airways' unsolicited tender offer to acquire all outstanding shares of Spirit's common stock."We are pleased that the Spirit Board of Directors has again reaffirmed its commitment to combining with Frontier, which increases competition by bringing more ultra-low fares to more travelers and delivering substantial shareholder value," said Barry Biffle, President and CEO of Frontier. "We are working with Spirit to complete our merger and create a true nationwide ultra-low fare airline to compete against the dominant 'Big Four' airlines and other high-cost airlines, including JetBlue. Together, we will super-charge the ultra-low-cost carrier model and create an even better option for consumers. He continued, "The Spirit Board of Directors took the right step in urging its shareholders to reject JetBlue's proposal and vote FOR the merger with Frontier. We continue to believe that JetBlue is worried about increased competition and put forward a proposal for a transaction that, simply put, can't be completed. We remain focused on moving forward with Spirit to drive competition and deliver enhanced value to all of our stakeholders." Frontier noted the following: "Unlike the compelling Spirit-Frontier combination, an acquisition of Spirit by JetBlue, a high-fare carrier, would lead to fewer options and more expensive travel for consumers. JetBlue has stated it will reduce capacity and raise fares on Spirit routes. The Transport Workers Union has publicly stated that it opposes JetBlue's proposed hostile takeover, noting JetBlue's intentions to eliminate thousands of jobs and low-cost flight options for customers as part of its proposal."

10:38 EDT Akamai rumor highlighted in Betaville 'Uncooked Alert' - Akamai Technologies is rumored as a takeover target, Betaville's Ben Harrington said in a blog post with a warning that the rumor is "Uncooked." Harrington's M&A blog defines an "Uncooked Alert" as "Market gossip as Betaville receives it. This scuttlebutt has just come in and hasn't been checked with all of Betaville's well-informed RARE sources let alone formal journalistic channels (public relations executives, bankers etc). The rumour might be total codswallop, rubbish or nonsense - but then again there may be something in it, so it's worth airing on Betaville." Reference Link

10:04 EDT Blackstone REIT completes $3.7B acquisition of Resource REIT - Blackstone announced that Blackstone Real Estate Income Trust has completed its previously announced acquisition of all of the outstanding shares of common stock of Resource REIT for $14.75 per share in an all-cash transaction valued at $3.7 billion, including the assumption of the REIT's debt.

10:01 EDT Under Armour falls -8.9% - Under Armour is down -8.9%, or -94c to $9.59.

10:00 EDT CI&T falls -10.9% - CI&T is down -10.9%, or -$1.49 to $12.23.

10:00 EDT Emergent BioSolutions rises 13.7% - Emergent BioSolutions is up 13.7%, or $3.87 to $32.21.

09:54 EDT Lennox boosts quarterly dividend by 15% to $1.06 per share - Lennox International said its board voted to increase its quarterly cash dividend 15% to $1.06 per share of common stock. The dividend is payable on July 15, to stockholders of record as of June 30.

09:47 EDT Harley-Davidson falls -10.3% - Harley-Davidson is down -10.3%, or -$3.69 to $32.06.

09:47 EDT Direxion Daily Jr Gld Mnrs Bull 3X Shrs rises 7.1% - Direxion Daily Jr Gld Mnrs Bull 3X Shrs is up 7.1%, or $3.28 to $49.60.

09:47 EDT Emergent BioSolutions rises 13.6% - Emergent BioSolutions is up 13.6%, or $3.86 to $32.20.

09:46 EDT Artisan Acquisition Corp trading resumes

09:41 EDT Artisan Acquisition Corp trading halted, volatility trading pause

09:35 EDT Dolphin Entertainment, Imax enter multiyear agreement for documentaries - IMAX Corporation and Dolphin Entertainment have entered into a multi-year agreement to jointly finance the development and production of a slate of feature-length documentaries for the global market. The first project greenlit by the partners is The Blue Angels, developed and co-produced by Bad Robot Productions and Zipper Bros Films. The Blue Angels is in production and is expected to hit IMAX theaters in 2023.

09:33 EDT Xvivo Perfusion says CHU Toulouse uses XVIVO technologies - The CHU Toulouse hospital in France has introduced both a liver and a lung machine perfusion program, now having the ability to significantly increase their transplant numbers. In a normal year they perform about 45 liver transplants and about 20 lung transplants and by that already fulfill the local requirement policy for organ transplantation. The machine perfusion programs also allow for utilization of organs donated after circulatory death.

09:31 EDT Enviva Partners enters MOU with MOL Drybulk to deploy EFBC - Enviva and MOL Drybulk announced they have signed an additional memorandum of understanding to deploy an environmentally friendly bulk carrier, or EFBC, to reduce the greenhouse gas, or GHG, emissions in the ocean transportation of sustainable wood pellets and biofuels. Following a successful joint study phase, the EFBC is scheduled for launch in 2024 and will aim to utilize rotor sail technology developed by Anemoi Marine Technologies together with MOL's 'Wind Challenger' technology, which would both reduce emissions by harnessing wind energy, for an expected average GHG savings of about 20% in total. The 62,900-deadweight tons vessel will be built by Oshima Shipbuilding.

09:30 EDT Jaguar Health to host Take C.H.A.R.G.E launch event - Jaguar Health is hosting a special media event and performance in New York City on Monday, May 23rd, 2022 from 12:30 to 2:30 PM Eastern to celebrate the launch of the Jaguar Health Canine Cancer: Take C.H.A.R.G.E. initiative - the first-ever U.S. Canine Cancer Registry and Cancer Care index - because protecting dogs from cancer begins with knowing its impact by breed, type, age, gender, and location.

09:28 EDT Zentek's Rapid Diagnostic Platform receives two NSERC grants - Zentek is pleased to announce that McMaster University has received two Natural Sciences and Engineering Research Council grants related to the aptamer-based rapid detection technology exclusively licensed by Zentek pursuant to its licence agreement dated April 11, 2021 with McMaster: The Alliance Missions Grant for the amount of $1,000,000, and an Idea to Innovation Grant for the amount of $350,000 of which Zentek will make a $140,000 contribution. Both of these awards are the maximum awarded under each respective grant program, with disbursements delivered over the next two years.

09:25 EDT Generac, PosiGen announce program to expand access to clean energy - Generac Grid Services, a subsidiary of Generac Power Systems, and PosiGen announced they will expand access to clean energy storage through a new program that offers state-of-the-art battery backup and load-management systems to residents. The program, believed to be a first of its kind in the nation, will also provide power back to the electrical grid, helping to increase grid stability, while reducing reliance on fossil fuels. Through the program, which will be facilitated by Generac Grid Services, PosiGen's solar customers in Connecticut will be able to obtain a Generac PWRcell battery and Generac PWRmanager load management system to pair with existing solar panels, to provide power to customers' homes when the grid goes down. Additionally, when tied to the grid and not providing backup power to the home, the PWRcell battery can be configured to provide up to 18kWh of usable energy back to the grid to help manage peak demand.

09:24 EDT Kohl's expects sales trends to strengthen for balance of year

09:22 EDT Imax, Dolphin Entertainment to jointly develop slate of documentaries - Imax Corporation (IMAX) and Dolphin Entertainment (DLPN) have entered into a multi-year agreement to jointly finance the development and production of a slate of feature-length documentaries for the global market. The first project greenlit by the partners is The Blue Angels, developed and co-produced by Bad Robot Productions and Zipper Bros Films. The Blue Angels is in production and is expected to hit IMAX theaters in 2023.

09:20 EDT Jamf Holding announces security, privacy management system certifications - Jamf recently achieved certification against the ISO/IEC 27701:2019 standard for the first time. In addition, Jamf successfully maintained certification against the ISO/IEC 27001:2013 standard. The positive audit conclusion against both standards was issued by an accredited certification body for these management system standards, Coalfire Certification. The scope of both certificates comprise operations supporting the Jamf Pro, Jamf Now, Jamf School and Jamf Protect solutions in Jamf's locations across Minneapolis, Eau Claire, Katowice and Emmen.

09:19 EDT Eneti announces purchase of common shares by Scorpio Holdings - Eneti announced that Scorpio Holdings Limited, a related party, has purchased 260,774 common shares of the Company at an average price of $6.53 per share in the open market. The Company currently has 40,738,704 common shares outstanding, of which SHL and its affiliates own 8,003,259 or 19.65%.

09:18 EDT Novan to present berdazimer gel 10.3% clinical data - Novan announced it will present Beginning of The End clinical data from its previously completed Phase 3 trial of berdazimer gel, 10.3% for molluscum contagiosum, B-SIMPLE4, at the Annual Meeting of the Society for Investigative Dermatology being held May 18-21, 2022 in Portland, Oregon. Berdazimer gel, 10.3%, containing the new chemical entity berdazimer, is in late-stage development and poised as a potential first-in-class topical controlled-nitric oxide releasing medication for the treatment of molluscum, a highly contagious viral skin disease affecting an estimated 6 million people in the US, mostly children, if approved. In June 2021, Novan reported statistically significant positive topline results for the primary efficacy endpoint of complete clearance of all treatable lesions in its B-SIMPLE4 pivotal Phase 3 clinical study of berdazimer gel, 10.3% for the treatment of molluscum. Additionally, and consistent with results from the Company's prior Phase 2 and Phase 3 studies, berdazimer gel, 10.3% was found to be well tolerated in the B-SIMPLE4 study and met Company expectations. No treatment-related serious adverse events were reported. BOTE sign observed in molluscum patients is known to be a sign of resolving molluscum contagiosum infection, but BOTE was never prospectively studied. Based on Novan's B-SIMPLE4 study data, patients with a positive BOTE sign at baseline had greater lesion reduction and clearance by Week 12 than patients with no BOTE or a negative BOTE sign at baseline, supporting the hypothesis that BOTE sign predicts molluscum contagiosum resolution. Patients who were both BOTE+ at baseline and treated with berdazimer gel, 10.3% had the greatest chance of molluscum clearance. The mechanism by which nitric oxide release hastens molluscum clearance is unknown but may be due in part to immunomodulatory activity as indicated by induction of BOTE, although other mechanisms may be involved. There are currently no FDA approved prescription therapies for the treatment of molluscum. The Company believes that berdazimer gel, 10.3% as a topical, prescription, self- or caregiver-applied therapy with a rapid treatment benefit, if approved, would satisfy an important patient-care need for the treatment of molluscum.

09:17 EDT J & J Snack Foods to acquire Dippin' Dots for $222M - J&J Snack Foods announced that it has entered into a definitive agreement to acquire Dippin' Dots, L.L.C., a leading producer of flash-frozen beaded ice cream treats, for $222 million, subject to customary purchase price adjustments. The transaction will be funded through a combination of cash and senior debt financing and is expected to be accretive to J&J's annual operating results and is anticipated to close by the end of June 2022, subject to customary closing conditions. An ice cream industry pioneer, Dippin' Dots uses an innovative and patented cryogenic freezing process to create unique "beaded" ice cream, yogurt, sherbet, and flavored ice products enjoyed by millions of consumers. The company sells its products through national accounts, local accounts, and a franchise network with over 140 franchisees. Dippin' Dots is headquartered in Paducah, KY, along with a main production facility, warehousing, distribution, and administrative offices. The Company also leases four additional frozen warehouses strategically located in California, Canada, Australia, and China. Ken Plunk, J&J Snack Foods Chief Financial Officer added "Dippin' Dots presents an opportunity to acquire a company that aligns with our focus on accelerating growth while delivering incremental shareholder value. Financially, we are leveraging our strong balance sheet and healthy liquidity position to acquire a profitable and scalable business that complements our long-term growth strategy. We expect this transaction to be accretive to our Earnings per Diluted Share in the range of $0.30 to $0.40 per share in the first 12 months after closing. This acquisition also provides significant tax benefits contributing to an even more attractive overall valuation."

09:16 EDT National Research Corporation appoints Parul Bhandari to board - National Research Corporation announced the appointment of Parul Bhandari to its Board of Directors, effective immediately. Since 2012, she has held various leadership roles at Microsoft. Currently, she is the Director, Partner Strategy, Worldwide Media and Communications.

09:14 EDT Nuvei to support Betsson in online sportsbook launch in the U.S. - Nuvei Corporation announces that it has partnered with Swedish-based online gaming operator Betsson Group to enable instant deposits and withdrawals on its proprietary online sportsbook in Colorado, in the U.S. which it launched under the brand name, Betsafe. Through its Instant Bank Transfer product, Nuvei is enabling players on the Betsafe online sportsbook to instantly deposit into their gaming accounts directly from their bank account. Players will also benefit from instant withdrawals, which enable them to receive their winnings straight into their bank account in real-time, 24/7. Nuvei Instant Bank Transfer's industry-leading player experience also tokenizes players' financial details when a first transaction is completed, meaning players are able to deposit or request a payout via a 'single click' payment method.

09:14 EDT Harley-Davidson sinks 10% after suspending all vehicle assembly - Shares of Harley-Davidson are moving lower after the company said it suspended yesterday all vehicle assembly and shipments, excluding LiveWire, for a two-week period. "This decision, taken out of an abundance of caution, is based on information provided by a third-party supplier to Harley-Davidson late on Tuesday (5/17) concerning a regulatory compliance matter relating to the supplier's component part," Harley-Davidson noted in a statement. Shares of the company are down 10%, or $3.75, to $32.00 in premarket trading.

09:13 EDT Biora Therapeutics announces patents for targeted therapeutics platform - Biora Therapeutics announced a new patent related to its Drug Delivery System platform under development. The USPTO has issued U.S. Patent No. 10,835,152 entitled, "Electromechanical pill device with localization capabilities" and allowed U.S. Application No. 15/940,407 entitled, "Localization systems and methods for an ingestible device." Their European counterparts, European Patent numbers EP3197336 and EP3600009, have also granted. The three patents and one allowed application are directed to ingestible devices capable of auto locating in the gastrointestinal tract using reflected light emitted from the device. The technology is broadly applicable to any ingestible device, whether the device is for sampling, diagnostics, or drug delivery. Biora's intellectual property covers the use of reflected light for autolocation by an ingestible device. This technology, as used in Biora's DDS capsule for its lead program, is designed to deliver a therapeutic dose to predefined locations in the lower GI tract, while simultaneously limiting degradation or systemic absorption in the upper GI tract. The proprietary autolocation technology is based on anatomical features that are consistent between humans and functions independently of physiological conditions such as pH, motility, pressure, and bacterial enzymes, which can vary greatly between individuals and disease states. The device's autolocation is designed to function autonomously, without reliance on external devices or magnets, and is cost-effective to build, without cameras or other complex electronic systems. The DDS platform can deliver liquid drug formulations, including peptides and proteins, which are difficult to formulate into orally available forms. The device has been used successfully in a human trial, and a clinical device performance study in active ulcerative colitis patients is currently recruiting.

09:12 EDT American Electric releases 2022 Corporate Sustainability Report - American Electric Power has issued its 2022 Corporate Sustainability Report, an annual assessment of its performance as a public company and a community partner. This report marks AEP's 16th year of environmental, social and governance, ESG, disclosure, demonstrating its commitment to reporting the company's progress toward a sustainable energy future. "As the economy embraces electrification to decarbonize the climate, our responsibility is to deliver clean, reliable and affordable electricity that is secure and resilient. At AEP, we add to that an obligation that the grid of the future provides equitable access for all its users. Our commitment to reach net-zero carbon emissions by 2050 is unwavering. We've already made significant progress and also committed to a just transition for our employees and our communities with a focus on inclusiveness, equity and collaboration," said Nicholas Akins, AEP's chairman, president and chief executive officer, in the report's introduction.

09:12 EDT Koil Energy receives order for hydrogen energy services - Koil Energy Solutions announced the receipt of an order to provide hydrogen energy related services. Following its recent rebrand, this is the company's first commercial success in support of the energy transition. The project will initially focus on storage, management and enhancement of customer furnished materials utilizing Koil's alloy welding and other fabrication capabilities. Following validation of early-stage activities, future phases could lead to systems integration activities potentially including the commissioning of systems being developed for the retail consumer market.

09:10 EDT NeuroMetrix's Quell wearable device receives FDA De Novo authorization - NeuroMetrix announced U.S. Food and Drug Administration De Novo authorization to market the Quell neuromodulation device as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity. The Company received FDA Breakthrough Designation for the use of Quell to treat fibromyalgia in July 2021. Fibromyalgia is a chronic condition characterized by generalized pain, fatigue, poor sleep, memory and concentration impairments, mood disorders and other disabling symptoms. These individuals experience low health-related quality of life and are twice as likely to be hospitalized as someone without fibromyalgia. The prevalence of fibromyalgia is estimated to be 2 to 6 percent of the U.S. adult population. The cause of fibromyalgia remains unclear, but scientific studies point to abnormalities in the way the central nervous system processes normal sensations and pain. Although a number of drugs are used to treat fibromyalgia only pregabalin, duloxetine and milnacipran have been approved by the FDA. These drugs are associated with side effects and generally poor adherence. Prior to Quell, the FDA had not approved or cleared any medical devices for treatment of fibromyalgia. The data submitted by NeuroMetrix in support of the De Novo request included results from a double-blind, randomized, sham-controlled trial. A total of 119 subjects with fibromyalgia were enrolled and randomized to a standard or modified Quell device for 3-months of at-home use. In a pre-specified subgroup analysis of subjects with high pain sensitivity, Patient Global Impression of Change was 1.25 points higher in the active arm compared to the sham arm. PGIC was the primary study outcome measure and represents a subject's overall belief about the efficacy of treatment on a 7-point categorical scale. The high pain sensitivity subgroup was defined based on Quantitative Sensory Testing and should represent the majority of fibromyalgia patients in real-world practice. In the intention-to-treat analysis of all randomized subjects, multiple secondary outcome measures were positive. For example, 57% of those on active treatment exhibited a clinically meaningful improvement in health-related quality-of-life compared to 34% that received sham treatment. Subjects in the active treatment arm reported statistically significant improvements in 19 of the 21 symptoms comprising the FIQR instrument, including pain, sleep, fatigue, balance and the ability to carry out typical daily activities. Some of the trial results were published in the Journal of Pain Research recently. A total of 9 adverse events were reported during the study and deemed to be definitely or possibly related to device use. All events were minor and self-limited. The most common occurrence was a rash under the Quell electrodes.

09:09 EDT Harley-Davidson suspends vehicle assembly, shipments for two-week period - Yesterday, Harley-Davidson took the decision to suspend all vehicle assembly and shipments for a two-week period. This decision, taken out of an abundance of caution, is based on information provided by a third-party supplier to Harley-Davidson late on Tuesday concerning a regulatory compliance matter relating to the supplier's component part.

09:08 EDT Banner Corp. says shareholders approved all proposals at annual meeting - Banner Corporation announced that shareholders approved all proposals and re-elected all director nominees at its 2022 Annual Meeting of Shareholders held virtually on May 18, 2022.

09:07 EDT Bit Digital announces interruptions to certain hosting partners' operations - Bit Digital (BTBT) announced updates related to its hosting partners' operations. Hosting partner Blockfusion USA advised the company that the substation at its Niagara Falls, NY facility was damaged by an explosion and subsequent fire, and power was cut off to approximately 2,515 of Bit Digital's bitcoin miners and approximately 710 ETH miners that had been operating at the site immediately prior to the incident. There is not believed to have been any material damage to the mining center building or to the Company's miners. The explosion and fire are believed to have been caused by the power utility. Blockfusion and the Company intend to pursue claims including seeking reimbursement for lost revenue. Blockfusion is working with its insurer and National Grid to restore power as quickly as possible. Operations are hoped to resume within a few weeks, but at this time there can be no assurances as to timing. Bit Digital management continues to monitor the situation and Blockfusion's pursuit of claims. Hosting partner Digihost Technology (DGHI) has advised the company that a cut in power to its North Tonawanda, NY site has resulted in approximately 1,580 of our miners going offline, citing the need for additional approvals from the power authorities. Digihost has made the applications and expects initial feedback this month. Digihost also continues to await approval from the New York Public Service Commission in order to complete its acquisition of the site's 60MW power plant; at this time there can be no assurances as to timing. Bit Digital management continues to monitor the situation.

09:06 EDT Helbiz partners with Austrlia-based allogio for e-scooter rental - Helbiz expands its e-scooter offerings to the Asia Pacific region for the first time through a strategic trial with alloggio, an operator of short-term rental accommodations in Australia. The program will begin in June, deploying at least 100 e-scooters to alloggio guests and staff, initially in Queensland, Australia, with plans for expansion into other tourism hotspots across the eastern coast of Australia. Leading Helbiz's newest region is Mitchell Price. As Regional Managing Director for Helbiz in the Asia Pacific Region, Mitchell will oversee the operations and expansion of Helbiz's micro-mobility program. Prior to joining Helbiz, Mitchell was Chief of Staff to an Australian Member of Parliament and senior executive for Lime and Superpedestrian in the APAC. Helbiz will initially provide scooters at some of alloggio's major holiday destination hubs including Noosa, Brisbane, and Magnetic Island in Queensland. The e-scooters are powered by 100% clean energy. The scooter ride can be started and paid for through the Helbiz app.

09:05 EDT Fastly acquires Glitch, terms undisclosed - Fastly announced it has acquired Glitch, a developer platform where more than 1.8M developers innovate, create, and share full-stack web apps without having to run the infrastructure or manage tools themselves.

09:04 EDT JetBlue responds to Spirit Airlines board recommendation to shareholders - JetBlue (JBLU) issued the following statement in response to the Spirit Airlines (SAVE) board recommendation: "It's no surprise that Spirit shareholders are getting more of the same from the Spirit Board. The Spirit Board, driven by serious conflicts of interest, continues to ignore the best interests of its shareholders by distorting the facts to distract from their flawed process and protect their inferior deal with Frontier. Regarding regulatory approval, Spirit would have you ignore the current regulatory climate to think that approval of their Frontier deal is assured. That is simply not true. Both deals are subject to regulatory review, and both deals have a similar risk profile. Spirit shareholders recognize that and are showing great interest in hearing more about our superior offer and the regulatory commitments and protections we have made, including a reverse break-up fee. Frontier offers less value, more risk, and no regulatory commitments, despite a similar regulatory profile. We are confident that as we continue to share the facts directly with Spirit shareholders, they will be even more perplexed than they already are about why the conflicted Spirit Board has refused to negotiate with us in good faith. We believe that the Spirit shareholders will make their views known by voting against the Frontier offer and tendering their shares into our offer."

09:03 EDT Leslie's appoints Claire Spofford to board of directors - Leslie's announced that it has appointed Claire Spofford to its Board of Directors. Ms. Spofford is Chief Executive Officer and President of J.Jill, and serves as a member of its Board of Directors.

09:03 EDT Crackle rolls out updated free app on Fire TV - Crackle announced the launch of the updated Crackle AVOD app on Fire TV. The free AVOD app is available to Fire TV US customers on all Fire TV devices. The Crackle AVOD app update includes state-of-the-art technology to deliver faster load times for the app itself as well as content screens and video playback. These backend improvements will also have an autoplay feature proven to dramatically increase user engagement, as well as a personalized content recommendation tool based on customers' previous viewing habits.

09:02 EDT Kohl's: Due diligence entering final phase

09:02 EDT Kohl's: Trends in May have 'notably' improved - Kohl's says the quarter started out strong with positive low single digit comp growth through late March, but demand "considerably weakened" in April as the company lapped last year's stimulus and as consumers started to experience inflationary pressures. The 200 stores with Sephora at Kohl's shops delivered positive low-single digits comp store sales growth for the quarter, Kohl's says. Comments taken from Q1 earnings conference call.

09:00 EDT EBET announces agreement with Captain Up - EBET announced an agreement signed by its subsidiary Esports Marketing Technologies with loyalty and engagement platform Captain Up. "With this deal, Captain Up will provide exciting in-play challenges, achievements, and a rewards shop for EBET brands," the company said. Captain Up CEO Uri Admon said, "This is the future of gaming: personal journeys, gamified shopping, and dynamic challenges. We are proud to join forces with the EBET family to add layers of gamification and customization that are tailored to each user in real time."

08:57 EDT LumiraDx five-minute SARS-CoV-2 Ag Ultra Test Achieves CE Marking - LumiraDx announced its SARS-CoV-2 Ag Ultra Test achieved CE Marking. The Ultra test provides digital and connected results in just five minutes with high sensitivity, making it one of the fastest and most sensitive COVID-19 antigen tests available. The LumiraDx SARS-CoV-2 Ag Ultra Test matches the same high-performance of the LumiraDx SARS-CoV-2 Ag 12 min test. In addition, the LumiraDx SARS-CoV-2 Ag Ultra Test demonstrated 95.7% positive agreement versus RT-PCR in samples collected from asymptomatic individuals. With the Omicron variant showing a much higher rate of asymptomatic carriage compared to other variants. Ron Zwanziger, LumiraDx's Chief Executive Officer explained, "Our SARS-CoV-2 Ag Ultra Test exemplifies our mission to increase access to testing and provide rapid diagnostics without sacrificing accuracy. Now, clinicians, pharmacies and other providers can use a single platform and significantly increase throughout, making a profound impact on patient workflow supported by our Platform. This innovation and advancement of our Microfluidic technology can also be applied to other tests on our Platform which we look forward to rolling out in the coming year."

08:54 EDT Trust Stamp partners with IdRAMP for biometric authentication - Trust Stamp announces a partnership with IdRamp. Together, they will launch an innovative biometric multi-factor authentication offering that can be augmented with a range of leading access management, social sign-on, and bring-your-own identity services, all through IdRamp's no-code platform.

08:54 EDT Converge Technology to acquire PC Specialists - Converge Technology Solutions is pleased to announce it has signed definitive agreements to acquire PC Specialists, Inc. d/b/a Technology Integration Group. Headquartered in San Diego, CA with 20 offices across North America, TIG specializes in optimized performance solutions and critical business support. From software and hardware procurement to discovery assessments, strategic planning, deployment, data center optimization, IT asset management and cloud computing, TIG offers custom-built IT solutions for clients around the globe, with a major presence in the United States and Canada. With 20+ branch locations, TIG serves a wide-reaching and diverse client base in enterprise, government, education, and SMB markets. Always offering a personal, consultative approach to identifying and fulfilling organizations' specific computing needs, TIG customizes innovative technology that best fits any unique infrastructure requirement. PC Specialists, Inc. d/b/a Technology Integration Group generated gross revenue1 of approximately C$423.0 million with an adjusted EBITDA of C$14.8 million for its most recently completed fiscal year ended October 31, 2021. Consideration for the purchase consists of US$74.0 million in cash to be paid at closing. Positive net working capital will also be paid out at closing. The purchase multiple is approximately 5.96 times adjusted EBITDA for the trailing twelve-month period ended October 31, 2021, after adjusting for positive working capital. The acquisition is expected upon closing to be immediately accretive to Converge, resulting in increased revenue and adjusted EBITDA.

08:50 EDT Genasys receives $1.5M in LRAD orders - Genasys announced foreign military sales and international defense orders totaling $1.5 million. Managed by the Department of State and executed by the Department of Defense, the FMS program sells defense products and services to foreign countries and international organizations that strengthen the security of the U.S. and promote world peace.

08:49 EDT EXL appoints Anita Mahon as head of EXL Health - EXL announced that it has named Anita Mahon Executive Vice President and Business Head of its EXL Health business unit. In this role, Mahon will work closely with healthcare payers, providers, pharmacy benefit managers and life sciences companies to develop data-led strategies that transform healthcare delivery, payment and management. She will also continue to serve as a member of EXL's Executive Committee. Previously serving as Executive Vice President and Chief Growth and Strategy Officer, Mahon has played a central role in shaping the trajectory of EXL's healthcare business over her past two plus years with the company.

08:48 EDT Allogene Therapeutics presents preclinical data on allogeneic CAR T cells - Allogene Therapeutics will present preclinical findings evaluating the characteristics and function of donor-derived allogeneic CAR T cells. Data showed that cells from a diverse set of younger donors had improved characteristics and better in vitro anti-tumor activity compared to cells from older donors. The study also showed that cells from patients with certain cancers generally performed suboptimally based on functional assays and often could not be used to generate viable CAR T therapies. The findings will be presented during an oral session at the 2022 American Society of Gene and Cell Therapy Annual Meeting at 10:45am ET. The study evaluated the characteristics and performance of CAR T cells derived from healthy donors aged 19 to 62, comparing the healthy donor cells to those derived from patients with cancer. Based on the analysis, CAR T cells produced from younger donors had stronger T cell phenotypes and better in vitro anti-tumor activity cytotoxicity compared to older donors. The expression of specific exhaustion and activation markers was also correlated with increased donor age and in vitro anti-tumor activity decreased with donor age. Regardless of age, the CAR T cells derived from healthy donors performed better and had a lower manufacturing failure rate compared to those derived from patients with cancer. Creating allogeneic CAR T cells from healthy donors reduces product variability; reduces the risk of manufacturing failures; and enables treatment within days, eliminating the need for bridging chemotherapy. This study provides additional evidence that younger, healthy donors may improve product characteristics and potency compared to older donors. Allogene currently has four clinical programs underway investigating the potential of AlloCAR T product candidates for the treatment of relapsed/refractory large B cell lymphoma, RR multiple myeloma and advanced renal cell carcinoma.

08:47 EDT mPhase Technologies renews software license agreement with channel partner - mPhase Technologies announced that it has amended and renewed its primary technology contract with its channel partner for an additional three-year term. This important contract is a follow-on to the original three-year license agreement dated June 30, 2019. The agreement currently generates about $8.4 million in quarterly revenue and more than $33 million in annual revenue. Under this renewed license, the channel partner gains the right to utilize the mPhase proprietary cloud-based software as part of its platform of global business solutions. The mPhase Intelligent AI platform is a powerful system that includes real time tracking of skill development, making it highly attractive for industry-specific business training applications. In addition to a monthly software subscription, mPhase is also providing training, maintenance, updates and other support functions for a monthly fee.

08:45 EDT Monro sees FY23 CapEx $40M-$50M - Sees FY23 operating expenses slightly lower on y/y basis.

08:43 EDT GlobalFoundries, Motorola announce strategic agreement for chip supply - GlobalFoundries (GFS) and Motorola Solutions (MSI) announced a long-term agreement to safeguard the supply of innovative chip solutions for Motorola Solutions' radios, which are widely used by public safety, critical infrastructure and enterprise organizations across the world. "Millions of first responders, utilities, infrastructure providers and businesses rely on Motorola Solutions radios for everyday and emergency communications, and it is essential that we maintain supply of these critical components," said Scott Mottonen, senior vice president of products, Motorola Solutions. "Our long-term relationship with GF provides important capabilities, reliable U.S.-based manufacturing and added assurance that we will continue to meet the safety and security needs of our customers across the globe."

08:41 EDT American Noble Gas acquires interests in oil, gas leases in Southern Kansas - American Noble Gas is pleased to announce that it has acquired a 60.7143% in GMDOC, LLC, a Kansas limited liability company, which has previously acquired working interests in certain oil and gas leases from Castelli Energy, L.L.C, an Oklahoma limited liability company. The GMDOC Leases cover approximately 10,000 acres located in Southern Kansas near the Oklahoma border. The GMDOC Leases currently produce approximately 100 barrels of oil per day and 1.5 million cubic feet of natural gas per day on a gross basis. On May 3, 2022, AMGAS entered into the operating agreement of GMDOC, pursuant to which the Company acquired 17 of 28 limited liability membership interests in GMDOC, for an aggregate purchase price of $4,037,500, and was subsequently admitted as a member of GMDOC. GMDOC had acquired 70% of the working interests in the GMDOC Leases from Castelli. GMDOC is managed by two other members - Darrah Oil Company, LLC, a Kansas limited liability company, and Grand Mesa Operating Company, a Kansas corporation - each of which also serve as the operating companies under the GMDOC Leases. Pursuant to the terms of the Operating Agreement, each member agreed to pay GMDOC, as its capital contribution, $50,000 in cash per Interest, with the remainder to be financed by a loan to GMDOC from a bank, secured by GMDOC's oil & gas lease properties, in the aggregate amount of $6,045,000. The principal of the bank loan is to be repaid in 84 varying monthly installments starting July 1, 2022, ranging from $170,000 at the beginning to $40,500 at the end of the loan term. The bank loan bears a variable interest beginning with an initial rate of 6% per annum with one rate adjustment after 36 months subject to a 6% minimum interest rate. Initial working capital was financed, in part, by a loan to GMDOC from a Managing Member, in the maximum aggregate amount of $400,000, which is to be repaid over 12 months and bears interest at a rate of 6% per annum. With respect to its cash capital contribution, the Company paid a non-refundable cash deposit for the Interests in the amount of $50,000 on May 3, 2022 and paid the remainder of the cash contribution for the Interests, or $800,000, on May 16, 2022. The remainder of the Company's capital contribution, or $3,187,500, was financed by the bank loan. The Company funded the cash contribution through the issuance of 8% Senior Unsecured Convertible Promissory Notes due June 29, 2022 to two institutional investors. The Company issued a total of 425,000 shares of common stock to these two institutional investors as additional consideration for such notes.

08:39 EDT SinglePoint's BOX Pure Air assisting schools in areas with wildfire smoke - SinglePoint subsidiary BOX Pure Air is actively assisting schools looking for immediate solutions to continue safely operating by addressing indoor air quality, IAQ, for students, teachers and staff in areas affected by wildfire smoke in an attempt to prevent unplanned school closures. Wil Ralston, CEO of SinglePoint commented, "For too long we have ignored the poor health conditions and the catastrophic effects of poor indoor air quality. Clean air is an essential right and we have a solution that can immediately improve indoor air quality in the places we gather, whether that be at home, at work, or at school. The particle size associated with wildfire pollution can quickly and dramatically harm anyone who breathes it in, but the portable HEPA air filtration system we offer cleanses the air of these pollutants, reducing the risk. Schools and students cannot afford to miss additional days due to dangers of the air they breathe indoors, especially when there is a simple, portable and effective solution."

08:38 EDT Monro has 'ample' capacity for acquisitions

08:37 EDT Captona acquires solar, storage facility with partner South Jersey Industries - Captona and South Jersey Industries announce a fourth acquisition through Catamaran Renewables joint venture for a 5.66 MW Solar and 5.2MWh Storage facility in Agawam, Massachusetts. Prior to the acquisition, Catamaran's portfolio included Solar and Fuel Cell assets. Adding Storage to its portfolio, Catamaran further strengthens its commitment to decarbonization. Catamaran Renewables acquired the Agawam Solar and Storage project from Consolidated Edison Solutions. The facility has qualified for the Massachusetts SMART program - a tariff-based incentive program for eligible solar technology assets - ensuring a strong return on investment as the facility continues to provide clean power to over 100 C&I community subscribers in Western Massachusetts.

08:36 EDT ShockWave Medical announces long-term data from Disrupt PAD III trial - Shockwave Medical announced that long-term data from the Disrupt PAD III trial found that superior vessel preparation with IVL led to excellent long-term outcomes out to two years with preservation of future treatment options compared to percutaneous transluminal angioplasty in the treatment of calcified peripheral artery disease. The final outcomes of the largest randomized trial of severely calcified peripheral lesions were presented by investigators today in a featured clinical research session at the 2022 Scientific Sessions of the Society for Cardiovascular Angiography & Interventions and published simultaneously in JSCAI. As previously published, IVL at 30 days demonstrated superiority over PTA in the primary endpoint analysis, defined as procedural success with a residual stenosis less than or equal to 30 percent without flow-limiting dissection, prior to drug-coated balloon or stent, with a rate of 65.8 percent versus 50.4 percent as determined by an independent angiographic core lab. Additionally, PAD III showed that IVL achieved a reduction in frequency and severity of flow-limiting major dissections a reduction in stent implantation rate and no distal embolization or perforation events. These new long-term results found that the powered secondary endpoint of primary patency favored IVL over PTA at one year and remained favorable through two years, respectively. Disrupt PAD III was a prospective, multicenter, randomized study designed to demonstrate the safety and effectiveness of IVL as a vessel preparation procedure in moderate to severely calcified superficial femoral and popliteal lesions, followed by a DCB or stent. The study enrolled 306 patients randomized between IVL and PTA at 45 sites in the United States, Germany, Austria, and New Zealand. In the IVL arm, 82.9 percent of patients were classified by the angiographic core lab as having severe calcification, with an average calcified lesion length of 129.4 millimeters. Joining Dr. Gray as co-principal investigator of the study was Gunnar Tepe, M.D., Head of the Department of Diagnostic and Interventional Radiology, RoMed Clinic Rosenheim, Germany.

08:34 EDT Sabre announces new distribution agreement with Viva Aerobus - Sabre announced a new distribution agreement with Viva Aerobus, Mexico's ultra-low-cost carrier, which will help enable the airline to power future revenue growth through agency sales. Viva Aerobus can now distribute its flights and services through Sabre's global distribution system, GDS, providing more content and choices through a single source for greater convenience, agility and efficiency. "With this agreement, Sabre-connected agencies will enjoy e-ticketing and enhanced merchandising capabilities, allowing travel agents to easily view, compare, and sell Viva Aerobus' flights across the network," the company said.. With the implementation of Sabre's branded fares technology, Viva Aerobus will now be able to provide their customers greater flexibility to choose products and services. "Viva Aerobus is an airline in constant expansion with solid plans for growth in fleet, routes and flights. Partnering with a trustworthy and innovative technology company like Sabre is key to both achieve our growth plans, as well as to increase operational efficiencies," said Andrea Rodriguez, Sales Director at Viva Aerobus. "We are confident that Sabre is the right partner to support our long-term goal, which is to provide travelers with the lowest fares and a personalized experience where they only pay for what they really need."

08:33 EDT Alcoa signs long-term renewable power contract to restart San Ciprian smelter - Alcoa signed a contract for renewable energy to support the planned restart in 2024 of aluminum smelting at the San Ciprian smelter in Spain. The long-term power purchase agreement is with Greenalia, an independent renewable energy developer and producer. Subject to windfarm permitting processes, the agreement would commence in 2024 and extend to the end of 2033. Due to exorbitant energy prices, Alcoa announced in December of 2021 a two-year curtailment of aluminum smelting at the site. During the curtailment, Alcoa is working to secure power purchase agreements and make improvements to prepare the smelter for the planned restart to begin in January of 2024. The agreement is expected to provide up to 183 MW of the smelter's baseload power consumption, representing approximately 45% of the energy required to meet the smelter's maximum capacity of 228,000 metric tons per year. The contract's pricing terms are confidential. Alcoa is continuing to pursue options for the remaining 55% of the smelter's electricity requirements. While the smelter is curtailed, the casthouse and the San Ciprian alumina refinery continue to operate.

08:32 EDT AcelRx provides update on reduced FDA REMS requirements related to DSUVIA - AcelRx Pharmaceuticals reported that the U.S. Food and Drug Administration, FDA, has recently modified the DSUVIA Risk Evaluation and Mitigation Strategies, REMS, requirements with respect to healthcare setting audits. The goal of the DSUVIA REMS program is to mitigate the risk of respiratory depression resulting from accidental exposure by ensuring that DSUVIA is dispensed only to patients in certified medically supervised healthcare settings. On April 21, 2022, the FDA revised the DSUVIA REMS program to eliminate the 6-month healthcare setting audit requirement and reduce annual healthcare setting audits to a total of up to 400 sites that have received a shipment of DSUVIA in the past 6 months. Previously, the DSUVIA REMS required AcelRx to audit all healthcare settings within six months of an initial DSUVIA order, and to then continue to audit all such sites annually thereafter, with no limit to the number of sites audited. "We continue to work closely with the FDA on the DSUVIA REMS program and have established a track record of compliance and safety with DSUVIA, including lack of accidental exposure," said Pamela Palmer, MD, PhD, Co-Founder and Chief Medical Officer of AcelRx. "We believe that it is this history of stewardship and responsibility, which is included in our latest three-year assessment REMS report as submitted to the FDA, that has resulted in the lowering of both the number and frequency of required site audits," continued Dr. Palmer.

08:29 EDT Glue42 adds AllianceBernstein as a client - Glue42 has added leading research and global investment firm AllianceBernstein to its client roster. The firm engaged Glue42 to support and organize its trader interface into a collection of micro applications that form a cohesive workflow. As part of this approach, AB's engineers will be able to build a framework that integrates and delivers apps in a timely manner and pushes new features to its traders daily - without disruption to the business. "The initial rollout has already demonstrated tremendous efficiency gains," said Tim Morbelli, Senior Vice President, Head of Emerging Markets and Municipal Trading, AllianceBernstein. "The Glue42 platform has taken the complexity out of integrating desktop, web, and third-party apps, giving flexibility to our engineers and quality assurances team as to how we develop, test, and distribute our applications, all while providing a cohesive experience regardless of who developed the app."

08:27 EDT Brickell Biotech doses first subject in Phase 1 study of BBI-01 - Brickell Biotech announced that the first subjects were dosed in the single ascending dose portion of the Company's Phase 1 clinical trial evaluating BBI-02 in healthy adult subjects and patients with atopic dermatitis. BBI-02 is a potential first-in-class, highly selective, orally bioavailable small molecule DYRK1A inhibitor that aims to restore immune balance through modulating adaptive and innate immune responses in patients with autoimmune and inflammatory diseases. The first-in-human Phase 1 trial of BBI-02 is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BBI-02 capsules in both healthy adult subjects and patients with AD. Part 1A of the study is a SAD assessment of BBI-02 or placebo in healthy adult subjects, and Part 1B of the study will be a multiple ascending dose assessment of BBI-02 or placebo administered once daily for 14 days in healthy adult subjects. After completing the SAD and MAD cohorts, Brickell plans to enroll Part 2 of the study, which will compare BBI-02 to placebo in patients with moderate-to-severe AD over 28 days of dosing and will include a preliminary assessment of efficacy. Topline results from the SAD and MAD parts of the Phase 1 trial are expected to be announced by early 2023.

08:25 EDT Energy Fuels secures rare earth land position in Brazil - Energy Fuels announces that it has entered into binding agreements to acquire seventeen mineral concessions between the towns of Prado and Caravelas in the State of Bahia, Brazil totaling 15,089.71 hectares. Based on significant historical drilling performed to date, it is believed that the Bahia Project holds significant quantities of heavy minerals, including monazite, that will feed Energy Fuels' quickly emerging U.S.-based rare earth element supply chain. The Bahia Project has seen no previous mining, but several of the concessions have valid exploration and mining permits with the Government of Brazil. Therefore, the Company believes there is a clear path to moving the Bahia Project to production. Mark Chalmers, President and CEO of Energy Fuels stated: "This is another very significant step in Energy Fuels' development as a major global rare earth element producer based in the United States. We are aggressively seeking to expand our monazite sand feeds. With guidance from our heavy mineral sand experts, the Company has been evaluating the acquisition of monazite-bearing projects. The Bahia deposit is well-known throughout the HMS industry as having excellent potential to produce high-quality ilmenite, rutile, and zircon products, in addition to monazite. We are very pleased to have secured this project, as it has the potential to provide Energy Fuels with our own low-cost source of monazite feed that we fully control. The Company expects to supplement its monazite supply in the future with open market purchases, arrangements with existing monazite producers, and/or additional acquisitions. Energy Fuels is in advanced discussions with other current and future monazite producers around the world to provide creative options on how to best build upon our momentum and add further scale."

08:24 EDT Adverum Biotechnologies presents research piepline data at ASGCT - Adverum Biotechnologies will announce new research pipeline data supporting the utility of its proprietary adeno-associated virus vector platform in ocular gene therapy. These new data will be featured in oral presentations during the American Society of Gene and Cell Therapy 2022 Annual Meeting in Washington, D.C. and virtually. "Adverum is an industry leader in the development of adeno-associated virus ocular gene therapy, including cassette engineering and vectorizing therapeutic proteins, and we are pleased to have multiple presentations highlighting our platform at ASGCT. As we continue to prepare for the initiation of a Phase 2 trial of ADVM-022 for wet AMD in the third quarter of 2022, we are also advancing other research programs toward the clinic and expanding our pipeline in ocular gene therapy by building on the potential of a single in-office intravitreal injection with our proprietary AAV.7m8 capsid," said Brigit Riley, Ph.D., chief scientific officer at Adverum Biotechnologies. "We are excited to present non-clinical data on ADVM-062 for blue cone monochromacy, which received Orphan Drug Designation by the U.S. Food and Drug Administration in January 2022, and continue to advance this program toward an investigational new drug application submission. Adverum continues the technical advances of our in-house adeno-associated virus manufacturing processes. Finally, we are maturing a portfolio of proprietary vectors with specific ocular cell tropism and are excited to showcase our innovative work on LSV1, a novel capsid for ocular gene therapy." ADVM-062 for Blue Cone Monochromacy: Data Highlights: ADVM-062 was well tolerated at all doses tested: No observed adverse effect level for the study was 3x10^11 vg/eye dose in non-human primate. LSV1 Data Highlights: Identified LSV1 from a library screen in NHP; LSV1 has a unique 3D structure at the 3-fold axis imparting new structural characteristics from parental backbone; LSV1 efficiently transduces NHP retina from the vitreous; High expression in the fovea and periphery, as well as retinal pigment epithelium expression

08:22 EDT Equinix highlights latest progress on ESG commitments - Equinix has released its 2021 Sustainability Report which outlines progress, innovation and accomplishments on key environmental, social and governance, ESG, commitments from the past year and since formalizing its Corporate Sustainability program in 2015. Keith Taylor, Chief Financial Officer, Equinix: "Our customers, partners, investors and employees are focused on sustainability more than ever. In the past year, we have seen a substantial increase in interest from customers on how Equinix helps them meet their sustainability and ESG objectives. Responding to our customers' needs is just one of the reasons we are devoted to our "Future First" sustainability strategy that outlines our key ESG initiatives and responsibilities, including diversity, inclusion and belonging (DIB), science-based targets and our commitment to becoming climate neutral globally."

08:20 EDT Cango announces Liu to resign as a director of the company - Cango announced that Xiaoyu Liu has tendered his resignation as a director of Cango for personal reasons. Liu's resignation became effective on May 19, 2022.

08:19 EDT Sterigenics announces increased electron beam sterilization capacity - Sterigenics announced the beginning of processing at its expanded electron beam facility located in Columbia City, Indiana. The Sterigenics Columbia City facility provides mission-critical E-beam sterilization services to help ensure the safety of medical devices and drug products used across the global healthcare industry. The new E-beam accelerator will significantly increase the capacity of the medical and pharmaceutical products that can be sterilized at the Columbia City facility.

08:18 EDT HP Inc. debuts new HP Spectre, HP Envy laptops - HP Inc. debuted its newest HP Spectre and HP Envy laptops built with the flexibility to create and live seamlessly in today's hybrid world.The new HP Spectre x360 13.5-inch 2-in-1 Laptop PC looks great and sounds great anywhere. The HP Spectre x360 13.5" engineered on the Intel Evo platform is expected to be available for purchase on May 19 at HP.com for a starting price of $1,249.99. The device will also be available at BestBuy.com and select Best Buy retail locations. The HP Spectre x360 16-inch 2-in-1 Laptop PC engineered on the Intel Evo platform is newly refreshed with the latest 12th Gen Intel Core processors and up to Intel Arc Graphics, bringing you the best in AI-based hands-free controls along with AI-based Privacy Alert, and screen time and distance reminders. The HP Spectre x360 16" is expected to be available for purchase on May 19 at HP.com for a starting price of $1,649.99. The device will also be available at BestBuy.com and select Best Buy retail locations. The HP Envy x360 13.3-inch 2-in-1 Laptop PC designed on the Intel Evo platform was co-engineered and optimized with Intel to offer up to 20.5 hours of battery life25 for all-day creation. The HP Envy x360 13" is expected to be available be available for purchase on May 19 at HP.com for a starting price of $899.99. The device will also be available at BestBuy.com and select Best Buy retail locations. The HP Envy x360 15.6-inch 2-in-1 Laptop PC is available with the latest Intel or up to AMD Ryzen 7 processors. The HP Envy x360 15.6" with AMD is expected to be available be available for purchase on May 19 at HP.com for a starting price of $849.99; the Intel version is expected to be available for purchase on May 19 at HP.com for a starting price of $899.99. Both versions will also be available at BestBuy.com and select Best Buy retail locations. The HP Envy 16-inch Laptop PC offers up to Intel Arc Graphics or NVIDIA GeForce RTX 3060 Laptop GPU. Coupled with DDR5 memory support and a gaming grade thermal solution, this device delivers optimal performance for multitasking, rendering 3D models, or when using powerful creative tools like Adobe Photoshop. The HP Envy 16" is expected to be available for purchase on May 19 at HP.com for a starting price of $1,399.99. The device will also be available at Amazon and other NA retailers. The HP Envy 17.3-inch Laptop PC gives you the power to create on a big screen. The HP Envy 17" is expected to be available for purchase on May 19 at HP.com for a starting price of $1,099.99. The device will also be available at BestBuy.com and select Best Buy retail locations.

08:16 EDT Kratos Defense, Minn-Dak Farmers Cooperative partner for self-driving trucks - Kratos Defense & Security Solutions announced that it has teamed with the Minn-Dak Farmers Cooperative to launch self-driving trucks, easing the truck driver shortage burden using Kratos Autonomous Systems to ensure integrity of the agriculture supply chain as a critical national security concern. Kratos Unmanned Systems' core competency is affordable, disruptive, unmanned systems-related technology and products for aerial drones, surface vessels, ground-based vehicles, and related command, control, autonomy, and artificial intelligence. The collaboration between Kratos and MDFC, one of America's largest sugarbeet shareholder/grower cooperatives, was fostered by Grand Farm, a non-profit group focused on facilitating agriculture technology innovation headquartered in North Dakota and combines Kratos' innovative unmanned system technologies, with Minn-Dak's agriculture and transportation expertise. The retrofitted solution adapts "Leader/Follower" truck platooning for hauling harvested sugarbeets between piling stations and the granulated sugar processing plant in Wahpeton, North Dakota.

08:13 EDT Ultragenyx announces durability data from Phase 1/2 AAV gene therapy studies - Ultragenyx announced longer-term efficacy and safety data from Phase 1/2 studies of DTX401 for the potential treatment of Glycogen Storage Disease Type Ia and DTX301 for the potential treatment of Ornithine Transcarbamylase deficiency. Results demonstrate ongoing durability of response and safety for both gene therapy programs as of the data cutoff date. Data were presented this week at the American Society of Gene & Cell Therapy 25th Annual Meeting. DTX401 Phase 1/2 Update: Longer-term Phase 1/2 data demonstrate durability of response, with sustained responses lasting more than 3.5 years since treatment. All 12 patients in the study continue to demonstrate improved glucose control, experiencing reductions in oral glucose replacement with cornstarch. Overall, patients reached a mean total daily reduction of cornstarch intake of 70% from baseline to the last available timepoint. Three patients in the first cohort have sustained responses for up to 3.5 years since treatment. Continuous glucose monitoring was introduced in the third cohort, and data indicate that these patients achieved significant reductions in average cornstarch intake while increasing the time spent in euglycemia, defined by blood glucose levels in the normal range of 60 mg/dL to 120 mg/dL. Specifically, average cornstarch intake was reduced by 65% at Weeks 49 to 52 compared with Weeks 1 to 4, while euglycemia increased by 14% in the same period. All three patients in the fourth cohort have completed a tapering prophylactic steroid regimen and have demonstrated reductions in daily cornstarch intake, while the average percentage of time in euglycemia for these patients remained stable. When patients were interviewed at 52 weeks, they reported more energy and stamina, better mental clarity, improved glycemic control independent from cornstarch, improved sleep quality and improvements in health-related quality of life related to cornstarch intake reduction. Patient Global Impression of Change scores at the Week 52 visit indicated that 67% of patients felt their GSDIa was moderately or much improved since the start of the study. Across the Phase 1/2 study, there have been no infusion-related adverse events and no treatment-related serious adverse events reported. DTX301 Phase 1/2 Update: Longer-term Phase 1/2 data show durable metabolic control and sustained responses lasting more than four years since treatment: Four out of the five patients treated at the highest dose - the dose specified for the Phase 3 study - have responded and remain clinically and metabolically stable. Overall, the seven responders of the 11 total patients treated across all cohorts remain clinically and metabolically stable. Six patients enrolled in the first three cohorts demonstrated durable response with 2 to 4.5 years of follow-up after treatment. One patient enrolled in the last cohort also achieved complete response prior to the 1-year follow-up. Four complete responders have discontinued ammonia-scavenger medications and liberalized their diet within one year. In the prophylactic steroid cohort, one of two patients demonstrated a complete response. The second patient was a responder at week 36, but viral infections and an inability to sustain increased protein intake in the presence of lowered medication led to catabolism. The patient was considered a nonresponder as of the 52-week visit. Once the patient is metabolically stable, we will reinitiate tapering of baseline disease management. Across all cohorts of the Phase 1/2 study, no treatment-related serious adverse events, infusion-associated reactions or dose-limiting toxicities have been reported. All reported adverse events have been Grade 1 or 2 during the main study except for one patient with Grade 3 hyperammonemic crises assessed as unrelated to DTX301. All patients have enrolled in the six-year extension study. No patient who received corticosteroids experienced an AE of increased ammonia, hyperammonemia, or hyperammonemic crisis that was associated with corticosteroid administration.

08:11 EDT VirTra receives notice of non-compliance from Nasdaq - VirTra received a written notice from The Nasdaq Stock Market on May 17, 2022, stating that because VirTra has not yet filed its Form 10-Q for the quarter ended March 31, 2022, it is no longer in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. This notification has no immediate effect on the listing of VirTra's shares on Nasdaq. However, if VirTra fails to timely regain compliance with Nasdaq Listing Rule 5250(c)(1), its common stock will be subject to delisting from Nasdaq. Under Nasdaq rules, VirTra has 60 calendar days to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rules. If Nasdaq accepts the plan, then Nasdaq may grant VirTra up to 180 days from the prescribed due date for filing the Form 10-Q to regain compliance. If Nasdaq does not accept the plan, then VirTra will have the opportunity to appeal that decision to a Nasdaq hearings panel.

08:10 EDT American Rebel to exhibit at NRA Annual Meetings and Exhibits - America's Patriotic Brand will exhibit at the NRA Annual Meetings and Exhibits May 27 - 29 in Houston, TX, at the George R. Brown Convention Center. American Rebel will be displaying its current line of Defender safes as well as its concealed carry line of products. AREB will also introduce two new product offerings, the American Rebel Freedom safe line and the American Rebel 2A Lockers.

08:09 EDT Jack Henry & Associates, Array announce collaboration - Jack Henry & Associates (JKHY) announced that Array's (ARRY) credit management services, identity protection tools, and offers engine will be integrated into the Banno Digital Platform, offering consumers personalized credit and financial insights through their trusted financial institutions. Array has leveraged the Banno Digital Toolkit, the same set of APIs the Banno Digital Platform is built on, to offer consumer credit and identity protection tools. Now, consumers can securely access and monitor their credit directly through their bank or credit union. Embedding this service protects consumers' data and reduces the risk of competitive products being sold.

08:08 EDT Permira completes acquisition of Mimecast - Mimecast announced the completion of its acquisition by funds advised by Permira for approximately $5.8 billion or $80.00 per share in cash. With the completion of the transaction, Mimecast's stock ceased trading and the company is no longer listed on any public market.

08:06 EDT Kyndryl, NetApp announce alliance to fast-track cloud transition - Kyndryl (KD) and NetApp (NTAP) announced a global alliance to help customers transform their businesses by unlocking insights from data stored on premises, in the cloud and edge computing environments. Under the alliance, Kyndryl and NetApp will collaborate to help customers across industries enhance and improve their ability to manage and extract business value from an avalanche of unstructured data including text-based documents, photos, audio and video files, IoT sensors and other sources. Specifically, the partners will align Kyndryl's IT infrastructure and managed services expertise with NetApp's strong leadership with the top public clouds along with its edge-to-core-to-cloud scalability to create new solutions that enable companies to access, analyze and derive insights from data that sits across multiple platforms and multiple clouds. "Increasingly the ability to manage and analyze large amounts of unstructured data in concert with traditional structured data is a key enabler of data-driven business transformation. NetApp's strategic partnership with Kyndryl enables joint delivery of critical data infrastructure services that will accelerate future innovation and business impact for customers and fast track cloud adoption," said George Kurian, CEO, NetApp. "This momentum and collective success within key industries made it clear it was time to elevate our relationship with Kyndryl and work together on solutions that address similar challenges in other data-centric market segments."

08:03 EDT Replimune Group expects cash to fund requirements into 2H24 - As of March 31, 2022, cash, cash equivalents and short-term investments were $395.7 million, as compared to $476.3 million as of March 31, 2021. The decrease was primarily related to cash utilized in operating activities in advancing the Company's expanded clinical development plan. Based on the current operating plan, Replimune believes that existing cash and cash equivalents and short-term investments will fund operating expenses and capital expenditure requirements into the second half of 2024, excluding any confirmatory trial required by the FDA or other regulatory body.

08:01 EDT Children's Place falls 10% to $39 after Q1 earnings and revenue

07:56 EDT 1933 Industries announces extraordinary meeting of debentureholders - 1933 Industries announces that it will hold an extraordinary meeting of holders of 10% Senior Unsecured Convertible Debentures Due September 14, 2021. The meeting details are as follows: Date: June 9, 2022; Time: 8:00 a.m. Debentureholders will consider the following amendments:To amend the conversion price applicable to the Debentures from $0.10 to $0.075 per share; To reduce the price per share for interest payments on the Debentures from $0.10 to $0.075 per share; To amend the price at which the Company may require a forced conversion of the Debentures from $0.15 to $0.10 per share, such conversion to be made at the amended Conversion Price of $0.075 per share; To extend the maturity date for the Debentures from September 14, 2022 to September 14, 2023

07:50 EDT Indaptus Therapeutics jumps 33% to $3.33 after FDA clearance of IND application

07:47 EDT Teva EVP of R&D sells $1.07M in common stock - In a regulatory filing, Teva disclosed that its EVP of R&D Hafrun Fridriksdottir sold 130K shares of common stock on May 17th in a total transaction size of $1.07M.

07:44 EDT Marimaca Copper announces results from RC drill holes at MOD - Marimaca Copper is pleased to announce the results from the first five reverse circulation drill holes, totaling 1,000m, targeting the depth extensions of the Marimaca Oxide Deposit in the area known as the MAMIX Zone. Drilling was designed to step-out from the original MAMIX discovery, as well as to commence infill drilling in some of the high-grade areas identified in previous drilling. The results have positive implications for the Mineral Resource Estimate update planned for Q3 2022. Highlights: MAR-19 extended intersected 420m at 0.54% CuT from surface, including the new re-entry intersection of 120m of 0.50% CuT from 300m; Drilling continues to demonstrate the thickness of the mineralized column at the MOD and significant extension into the MAMIX zone; Extensions identified to the south-west and south-east from the high grade central MAMIX zone; Re-entry hole LAR-49Ext intersected a broad zone of higher-grade mixed copper oxides and extends MAMIX mineralization to the south-west beyond the edge of the PEA open pit; LAR-49 extended intersected 292m of 0.34% CuT from 18m, including the new re-entry intersection of 90m of 0.39% from 220m; Complements and extends previous results from infill drill hole LAR-87 which intersected 288m of oxide mineralization from surface including 46m of 0.41% CuT from 258m, also extending outside the PEA open pit; MAR-12 Ext and MAR-34 Ext extend the MAMIX mineralization to the south-east well beyond the limits of the previously defined area of the MAMIX Zone; MAR-12 extended intersected 320m at 0.30% CuT from surface, including the new re-entry intersection of 170m of 0.24% CuT from 150m, including a higher grade intersection of 42m of 0.54% from 278m; MAR-34 extended intersected 224m at 0.47% CuT from 106m, including the new re-entry intersection of 60m at 0.26% from 270m including a higher-grade zone of 24m at 0.50% CuT from 306m; Expected to have positive implications for MAMIX resource potential and the upcoming MRE update; Re-entry depth extensions of MAR-51 Ext and MAR-26 Ext intercepted thinner, lower grade, zones interpreted to be impacted by NW-SE trending fault structures. Sergio Rivera, VP Exploration of Marimaca Copper, commented: "This drilling was largely designed to test potential for lateral extensions to the MAMIX Zone, which we discovered last year. The results are positive and confirm our interpretation that the MAMIX Zone is open in several directions. LAR-49 intersected a broad zone of good grades with several zones of higher-grade mineralization. Importantly, the results confirm, and step out from, the previously reported results from infill hole LAR-87 which intersected MAMIX style mineralization at depth. MAR-12Ext and MAR-34Ext both significantly extend MAMIX mineralization to the south-east. MAR-51, which was also a step out hole, was drilled very close to a NW trending structure, which explains its lower grade and thinning mineralization. MAR-19Ext was an outstanding drill hole and confirms excellent continuity of the higher grade core of MAMIX zone at depth in the centre of the previous discovery area. Overall, we are very pleased with the first results from MAMIX and we continue to believe it will add material tonnes and grade to our upcoming MRE update."

07:43 EDT Siga Technologies receives FDA approval for IV formulation of TPOXX - SIGA Technologies announced that the U.S. Food and Drug Administration approved the intravenous formulation of TPOXX for the treatment of smallpox. The IV formulation is an important option for those who are unable to swallow the oral capsules of TPOXX. The oral formulation of TPOXX is approved in the US, Canada and Europe for the treatment of smallpox. The European approval also includes the treatment of monkeypox, cowpox, and complications from immunization with vaccinia. The IV formulation of TPOXX was cited in the recent U.S. president's budget request as being used to treat a patient in the U.S. with monkeypox.

07:41 EDT MindMed reports data from Phase 1 trial of MM-110 - Mind Medicine announced topline results from the Phase 1 placebo-controlled trial designed to assess the safety, tolerability, pharmacokinetics and neurocognitive effects of MM-110 in 108 healthy volunteers. The results showed favorable safety and tolerability, support the advancement of MM-110, and have guided the Phase 2a dose, schedule, and design in individuals undergoing supervised opioid withdrawal. A total of 72 participants received up to 325 mg of MM-110 twice on a single day or placebo, and 36 participants were administered up to 90mg of MM-110 twice daily for seven days or placebo. The topline results and observations include the following: MM-110 was well-tolerated up to 500mg per day in the single ascending dose arm and 60 mg per day for seven days in the multiple-ascending dose arm of the trial. A linear pharmacokinetic profile was maintained across the tested doses and frequencies. Observed clinical effects demonstrated alignment with potent CNS engagement. No serious adverse events were reported. Treatment emergent adverse events were mild or moderate in severity and resolved without sequelae. Clinical laboratory parameters and electrocardiograms were also assessed with no findings of clinical concern across the administered dose ranges. Next steps: Consistent with the Phase 1 trial and aligned with the preclinical data, an every-other-day dose regimen is planned for the Phase 2a trial. This dose schedule offers the potential to be a better option than existing treatments for supervised opioid withdrawal.

07:40 EDT Uxin receives Nasdaq notice of non-compliance - Uxin announced that it has received written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market dated May 18, 2022, indicating that for the last 30 consecutive business days, the closing bid price for the Company's American depositary shares was below the minimum bid price of US$1.00 per share requirement set forth in Nasdaq Listing Rule 5450(a)(1). The Nasdaq notification letter has no current effect on the listing or trading of the Company's securities on Nasdaq. Pursuant to the Nasdaq Listing Rules 5810(c)(3)(A), the Company is provided with a compliance period of 180 calendar days, or until November 14, 2022, to regain compliance under the Nasdaq Listing Rules. If at any time during the 180-day compliance period, the closing bid price of the Company's ADSs is US$1.00 per share or higher for a minimum of ten consecutive business days, Nasdaq will provide the Company written confirmation of compliance and the matter will be closed. In the event the Company does not regain compliance by November 14, 2022, subject to the determination by the staff of Nasdaq, the Company may be eligible for an additional 180-day compliance period. The Company's business operations are not affected by the Nasdaq notification letter. The Company intends to monitor the closing bid price of its ADSs between now and November 14, 2022 and will take all reasonable measures in order to regain compliance with the Nasdaq minimum bid price requirement.

07:38 EDT Clene receives $3M loan from State of Maryland for manufacturing facility - Clene announced that the Maryland Board of Public Works has finalized a $3 million loan facility with Clene Nanomedicine. The loan was provided by the state's Neighborhood BusinessWorks program within the Maryland Department of Housing and Community Development. This non-dilutive loan for capital equipment purchases will support the expansion of Clene's operations in Cecil County, Maryland, at a new commercial manufacturing facility for production of its lead drug candidate, CNM-Au8, a gold nanocrystal suspension. The purchased capital equipment will secure the loan. This expansion is aligned with Clene's anticipation of the potential commercialization of CNM-Au8 as a treatment for amyotrophic lateral sclerosis. Clene expects topline data in the third quarter of 2022 from a Phase 2/3 registrational study, the HEALEY ALS Platform trial, evaluating CNM-Au8 in ALS patients.When fully developed and operational, Clene's 75,000-square-foot facility is expected to bring hundreds of new jobs to Cecil County in a federally Qualified Opportunity Zone in Elkton, Maryland.

07:37 EDT Just Energy announces transfer of listing from TSX Venture Exchange to NEX - Just Energy Group announced that in response to the Company's previous announcement on May 13, 2022 of a proposed plan of compromise and arrangement involving the Company, the TSX Venture Exchange was transferring the Company's listing from the TSX Venture Exchange to the NEX, effective at the opening of the market on Friday, May 20, 2022. The trading symbol for the Company will change from JE to JE.H. There is no change in the Company's name or CUSIP number.

07:37 EDT ObsEva appoints Annette Clancy as chair of the board - ObsEva announced the appointment of Annette Clancy as Chair of the Board of Directors at the Company's Annual General Meeting on May 18, 2022. Ms. Clancy has served as a member of ObsEva's Board of Directors since 2013 and was previously Chair from November 2013 to December 2016. Ms. Clancy succeeds Dr. Frank Verwiel, who had decided to step down from the role of Chair and retire from the Board of Directors, effective following the conclusion of the Annual General Meeting. Since her retirement from GSK in 2008, Ms. Clancy has advised venture capital health groups in the United States and Europe, namely as an Operational Investor for Jeito Capital and previously a Senior Advisor to Frazier Healthcare Ventures.

07:36 EDT Barrick Gold extends revolving credit facility - Barrick Gold announced that it has completed an amendment and restatement of the company's undrawn $3.0 billion revolving credit facility, including an extension of the termination date by one year to May 2027, replacement of LIBOR with SOFR as the floating rate mechanism related to the interest rate for any US dollar funds drawn down, and the establishment of sustainability-linked metrics. The sustainability-linked metrics incorporated into the revolving credit facility are made up of annual environmental and social performance targets directly influenced by Barrick's actions, rather than based on external ratings. The performance targets include Scope 1 and Scope 2 greenhouse gas emissions intensity, water use efficiency, and Total Recordable Injury Frequency Rate 1. Barrick may incur positive or negative pricing adjustments on drawn credit spreads and standby fees based on its sustainability performance versus the targets that have been set.

07:35 EDT Ocuphire Pharma trading halted, news pending

07:33 EDT Verano Holdings announces opening of MUV Ocala - Verano Holdings announced the opening of MUV Ocala on Friday, May 20, the Company's 47th Florida dispensary and 98th nationwide. MUV Ocala, located at 3701 SW College Road, is open Monday through Saturday from 9:00 a.m. to 7:00 p.m. and Sunday from 11:00 a.m. to 5:00 p.m., local time. MUV Ocala is located in Marion County, a rapidly growing area that experienced a population increase of 13.5% from 2010 to 2021. Ocala was also recently named the sixth fastest-growing city in the United States.

07:32 EDT Ocuphire Pharma says LYNX-1 Phase 3 trial met primary endpoint - Ocuphire Pharma announced topline results from the LYNX-1 Phase 3 pivotal clinical trial investigating its product candidate Nyxol for night vision disturbances. Across 12 US clinical trials with approximately 1100 subjects, over 650 subjects have now been exposed to Nyxol. NVD is a condition in which unfocused rays of light derived from imperfections in the periphery of the cornea manifest as reduced image quality when the pupil dilates in dim light conditions. Patients with NVD experience glare, halos, starbursts, and decreased contrast sensitivity. The effects of NVD can be mitigated by moderately reducing pupil diameter to eliminate some of the aberrations and their scattering effect, without impeding the ability to see in dim light due to reduced retinal illumination. Highlights of LYNX-1 NVD Phase 3 Results" LYNX-1 is a registration trial for Nyxol in this chronic NVD indication, and was designed as a randomized, double-masked, placebo-controlled, Phase 3 study to evaluate the safety and efficacy of Nyxol compared to placebo. In the trial, 145 study participants who experienced vision impairment under dim light conditions were randomized to receive either Nyxol or placebo, self-administered in each eye daily, at or near bedtime, over 14 days. The primary endpoint was the gain of 3 lines or more of distance vision improvement on a low contrast chart in dim light conditions. Baseline demographics and ocular characteristic means were well-balanced across Nyxol and placebo treatment arms. Highlights of the patient population include a mean age of 46 years with participants ranging from 19 to 70 years old; subjects with a mix of light and dark irides; mean baseline mesopic pupil diameter of 6.1 mm; and mean distance visual acuity of only 17 letters under mesopic low contrast conditions. Summary of LYNX-1 Data: The FDA-agreed primary endpoint was met, with a statistically significant greater percentage of Nyxol-treated subjects having gained 15 or more letters of mesopic low contrast distance visual acuity at Day 8, compared to placebo. Key secondary efficacy endpoints were also met with statistical significance: The effect of Nyxol increased at Day 15, with 21% of subjects gaining 15 or more letters of mLCVA compared to 3% placebo; Nyxol significantly increased the percentage of subjects gaining 10 or more letters of mLCVA at both Day 8 with 41% vs. 22% placebo and at Day 15 with 44% vs. 23%; Nyxol showed a favorable safety and tolerability profile: There were no serious adverse events; Adverse events occurring in Nyxol-treated subjects were predominantly mild in severity and were consistent with those observed in previous trials.

07:28 EDT ObsEva says shareholders approved all board proposals at 2022 meeting - ObsEva announced that shareholders approved all Board proposals at its 2022 Annual General Meeting held on May 18, 2022. The approved items are as follows: Shareholders approved the Annual Report, the Statutory Financial Statements and the Consolidated Financial Statements for Fiscal Year 2021; Shareholders granted discharge to the Members of the Board of Directors and to the Executive Committee for year 2021; Shareholders approved the proposed appropriation of the Financial Results for year 2021; Shareholders approved the proposed elections to the Board of Directors and election of the Chairperson of the Board of Directors; Shareholders approved the proposed elections to the Compensation Committee; Shareholders approved the re-election of PricewaterhouseCoopers SA as ObsEva SA's Auditors and Independent Registered Public Accounting Firm; Shareholders approved the re-election of Perreard de Boccard SA as Independent Representative; Shareholders approved the proposed compensation of the Board of Directors and the Executive Committee; Shareholders approved the proposed increase of ObsEva SA's Authorized Share Capital; Shareholders approved the proposed increase of ObsEva SA's Conditional Share Capital for Financing Purposes; Shareholders approved the proposed increase of ObsEva SA's Conditional Share Capital for Equity Plans; Shareholders approved the proposed change to ObsEva SA's Equity Incentive Plan; Shareholders approved the Issuance of Conversion Shares and Warrant Shares under Securities Purchase Agreement.

07:24 EDT Indaptus announces FDA clearance of IND application to Decoy20 trial - Indaptus Therapeutics announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug application for a Phase 1 clinical trial in patients with advanced solid tumors where currently approved therapies have failed. The Company plans to initiate the clinical trial in the second half of 2022.

07:22 EDT TScan Therapeutics presents preclinical data from solid tumor program - TScan Therapeutics presented two posters and an oral presentation around TScan's proprietary platform technologies for its solid tumor program at the American Society of Gene and Cell Therapy 25th Annual Meeting. Presentation Highlights: Poster presentation titled "Discovery of TSC-200-A02: A natural HPV16 E7-specific TCR-T cell therapy candidate for the treatment of HPV-positive solid tumors," presented by Gavin MacBeath, Ph.D. Using TScan's proprietary ReceptorScan platform, 453 putative HPV16 E7-specific TCRs were discovered by screening 681 million naive CD8+ T cells from 15 unique healthy donors and testing each TCR for expression in primary T cells and for its ability to kill cells pulsed with the E7 peptide, using a National Cancer Institute HPV TCR as a benchmark. ReceptorScan identified a lead TCR, TCR-200-A02, and showed comparable cytotoxicity to the therapeutic TCR from NCI that has previously shown a 50% objective response rate in a Phase 1 clinical trial. SafetyScan, an array-based screening technology for off-target reactivity, showed that TCR-200-A02-expressing CD3+ T cells did not cross-react with 108 out of 110 of the most common HLA types in the US population, allowing this TCR-T to be used in the vast majority of patients. Additionally, TCR-200-A02 showed no reactivity to normal cells from healthy HLA-A*02:01+ human donors, indicating no off-tumor reactivity risk. Treatment with TCR-200-A02 showed significant inhibition of tumor growth in immunocompromised mice inoculated with HPV positive tumor cell lines. TScan has designed a transposon-based vector to deliver TSC-200-A02, along with genes for CD8alpha/beta and a dominant-negative form of TGFbeta Receptor II, into both CD4+ and CD8+ T cells. T cells expressing this vector were able to efficiently overcome TGFbeta-mediated suppression. These results validate the use of ReceptorScan and SafetyScan as a way to rapidly identify naturally occurring, high affinity, and derisked TCRs suitable for clinical development. The Company has advanced this TCR-T into IND-enabling studies as TSC-200-A02. Poster presentation titled "Multiplexed TCR-T cell therapy: A strategy to enhance the efficacy of engineered T cell therapy," presented by Gavin MacBeath, Ph.D. Variable inter- and intra-tumoral antigen expression was observed in human melanoma tumor samples as shown by heterogenous antigen expression of PRAME and MAGEC2 that varied from cell to cell within the same tumor. Non-small cell lung cancer samples showed wide prevalence of clonal and partial HLA LOH of the HLA-A*02:01 allele occurring in ~40% of NSCLC samples indicating that these tumors would not have responded to single TCRs targeting HLA-A*02:01 epitopes. Previous studies have indicated that this HLA LOH occurs through deletion of an entire chromosome arm where the HLA genes are located. Synergistic cytotoxicity was observed when HPV+ and MAGEA1+ cell lines were grown in the presence of an HPV16 E7-TCR-T and MAGEA1-TCR-T combination. MAGEA1-specific TCR-T cells co-cultured with a target cell line with high expression of MAGEA1 synergistically enhanced the cytotoxicity of MAGEC2 TCR-T cells co-cultured with a cell line with moderate MAGEC2 expression. The increased cytotoxicity was driven by cytokines secreted by MAGEA1-targeted T cells, leading to increased activation of MAGEC2-targeted T cells. These data suggest that a multiplexing approach can synergistically address target heterogeneity. TScan has devised a screening strategy to select patients for multiplexed TCR therapy. This includes germline HLA genotyping, followed by tumor assessment for target expression and HLA LOH. If LOH is observed, TCRs are chosen that target two different HLAs on the intact chromosome, which cannot be lost. If LOH is not observed, TCRs are chosen that target HLAs on opposite chromosomes to avoid secondary LOH. TScan's ImmunoBank enables customized multiplexing of TCRs across both targets and HLAs, which is designed to prevent resistance arising from either target loss or HLA LOH. These findings support the hypothesis that multiplexed TCR-T has the potential to overcome antigen heterogeneity not only through independent targeting of different target cells in the same tumor, but also by cytokine-mediated enhancement of each T cell's response. Oral presentation titled "Discovery of a novel C*07:02-restriced epitope on MAGE-A1 and pre-clinical development of an enhanced TCR-T cell therapy candidate for the treatment of solid tumors," presented by Gavin MacBeath, Ph.D. TScan's proprietary technology, TargetScan, allowed for the identification of TCRs and cancer antigens from a head and neck cancer patient who exhibited substantial tumor reduction after only eight weeks of checkpoint therapy. Two different expanded T cell clones from the patient's tumor shared a common TCR directed to a novel C*07:02-restricted epitope of MAGEA1 which was a potential driver of the anti-tumor response. MAGEA1 is a cancer/testis antigen expressed in various cancers but not normal tissues except for testis which is an immune privileged organ. MAGE-A1 is expressed in ~50% of melanoma and non-small cell lung cancer and high expression is correlated with poor survival. SC-204-C07 displayed strong cytotoxicity and cytokine secretion in response to HLA-C*07:02 positive cell lines that expressed MAGEA1 but not a cell line that lacked MAGEA1 expression, indicating no risk of off-tumor reactivity. Our results suggest that TargetScan can identify relevant tumor antigens and TCRs from expanded T cell repertoires of patients exhibiting strong and durable responses to checkpoint therapy, thereby providing suitable TCRs for clinical development.

07:18 EDT TPI Composites approves changes to corporate governance policies - TPI Composites announced that its Board of Directors has approved certain additional changes to the Company's corporate governance policies and practices. The Board has approved an amendment to the Company's bylaws to implement a majority voting standard for uncontested director elections, effective January 1, 2023. In addition, the Board has committed to putting to a stockholder vote at the 2023 Annual Meeting of Stockholders a proposal to eliminate the supermajority vote requirement to adopt, amend or repeal certain provisions of the Company's charter and bylaws. These newly announced changes are in addition to the Board already seeking stockholder approval to declassify the Board at the upcoming annual meeting. The Company's new majority voting standard will be effective January 1, 2023 and will apply to all future elections, but will not impact the results of the 2022 Annual Meeting, for which voting has already commenced. When effective, the new majority voting standard will require each director nominee to submit, in advance of such nomination, an irrevocable resignation, subject to acceptance by the Board, that would become effective if such nominee does not receive more votes properly cast in favor of his or her election or re-election than votes properly cast against such election or re-election. Previously, under a plurality voting standard, the candidates receiving the most affirmative votes were elected, regardless of whether those votes constituted a majority. Plurality voting will continue to apply in contested elections in which the number of director candidates exceeds the number of available positions.

07:15 EDT Alamos Gold enters automatic share repurchase plan - Alamos Gold announced that it has entered into an automatic share purchase plan with a broker in order to facilitate repurchases of Alamos' Class A common shares under its previously announced normal course issuer bid. Since December 24, 2021, Alamos has purchased 1.0 million shares in total pursuant to the NCIB at an average price of US$7.415 at a cost of $7.4 million, with all the purchases occurring in May 2022. During the effective period of the ASPP, Alamos' broker may purchase Common Shares at times when Alamos would not be active in the market due to insider trading rules and its own internal trading blackout periods. Purchases will be made by Alamos' broker based upon parameters set by Alamos when it is not in possession of any material non-public information about itself and its securities, and in accordance with the terms of the ASPP. Outside of the effective period of the ASPP, Common Shares may continue to be purchased in accordance with Alamos' discretion, subject to applicable law. The ASPP has been entered into in accordance with the requirements of applicable Canadian securities laws. Alamos previously announced that it had received approval from the Toronto Stock Exchange to, during the 12-month period commencing December 24, 2021 and terminating December 23, 2022, purchase up to 29,994,398 Common Shares, representing approximately 10% of the Company's public float of the Common Shares as of December 15, 2021, being 299,943,980 Common Shares, by way of a NCIB on the TSX or through alternative trading systems or by such other means as may be permitted under applicable law.

07:13 EDT Wabash announces 2025 EPS target of $3.50, revenue target of $3B - Wabash is hosting a virtual investor meeting at 10:00 a.m. EDT today, where members of the leadership team will present the company's refreshed strategy, growth initiatives and 2025 financial targets. Wabash is announcing the following financial targets for 2025: Revenue of $3.0B; EBITDA margin of 11%; EPS of $3.50. "We are excited to share how we are executing our refreshed strategy and accompanying growth initiatives," said President and Chief Executive Officer Brent Yeagy. "Accelerated R&D and product development leveraging the voice of the customer is in the early stages of generating new products that solve our customers' most important needs. By becoming a holistically more customer-centric organization, we expect to see the customer value we create accrue to our shareholders as our financial performance accelerates." Leadership presentations will cover how the company is delivering the only true First to Final Mile portfolio; industry-leading R&D activities that poise Wabash to capture significant market opportunity; and how sustainability is at the core of Wabash's strategy and increases value to its customers. Wabash's strategic growth initiatives center on three key areas: Cold Chain - Wabash's innovative EcoNex Technology offers superior thermal capability, lighter-weight, reduced corrosion and extended asset life - resulting in operational efficiency, while enhancing the sustainability initiatives of our customers. The scalability of EcoNex throughout Wabash's First to Final Mile portfolio is substantial and evidenced by the success of our recently launched grocery home delivery vehicle. Recurrent Revenue in Parts and Services - The creation of a new tech-enabled Wabash parts distribution network will unify and expand Wabash's parts distribution capabilities across all product lines and provides immediate scale to grow. Ecommerce and Logistics Disruption - Shifting consumer buying patterns have dislocated traditional logistics models, driving a structural increase in the volumes and types of equipment needed from first to final mile. This shift offers an opportunity for Wabash to bring new and refreshed product offerings to market to help customers thrive in a time of rapid change.

07:12 EDT Anterix announces launch of new integrated platform - Anterix announced the launch of an integrated platform to accelerate the scale benefits of a "network" of individual private broadband networks. At the center of this integrated platform will be a cloud-based 4G/5G core, enabling greater resilience and enhanced services between participating networks. The platform will also offer a development and innovation environment for the more than seventy-five leading technology companies in the Anterix Active Ecosystem, to drive products and services directly to utility network operators. "While the core of our offering remains focused on providing the spectrum needed to enable utility private broadband networks, this transition to a broader suite of solutions is in response to our customers' needs. The premise of this effort is that we all are stronger together. This platform capitalizes on the utility industry's well-established culture of collaboration, providing our more than seventy-five Active Ecosystem members with the collective voice of their utility customers. As the USAB identifies the industry's needs, Anterix and the Active Ecosystem community are there to deliver," said Rob Schwartz, President & CEO of Anterix.

07:10 EDT Centennial Resource, Colgate Energy to combine in merger of equals - Centennial Resource Development and Colgate Energy Partners III announced they have entered into an agreement to combine in a merger of equals transaction. The combined company will be the largest pure-play E&P company in the Delaware Basin with approximately 180,000 net leasehold acres, 40,000 net royalty acres and total current production of approximately 135,000 Boe/d. The combined company plans to leverage its high-quality, scaled asset base to drive leading shareholder returns. Key Highlights: High-quality, complementary asset base with differentiated inventory depth to support sustainable free cash flow growth; Positioned to significantly increase cash returns to shareholders, with over $1 billion of expected free cash flow in 2023 at current strip prices; Highly accretive to key financial metrics, including cash flow, free cash flow and net asset value per share; Strong balance sheet with expected leverage below 1.0x at year-end 2022; Sean Smith to serve as Executive Chair of the Board; Will Hickey and James Walter to serve as Co-CEOs; Significant equity ownership of combined management team aligns with shareholders; Shared commitment to prioritizing ESG with continued focus on reducing environmental impact. The approximately $7.0 billion merger of equals values Colgate at approximately $3.9 billion and is comprised of 269.3 million shares of Centennial stock, $525 million of cash and the assumption of approximately $1.4 billion of Colgate's outstanding net debt. Given existing cash balances and interim free cash flow, the company expects its net debt-to-LTM EBITDAX ratio at closing to be approximately 1.0x. The cash consideration and the repayment of Colgate's outstanding credit facility borrowings at closing are expected to be funded with cash on hand and borrowings under an upsized revolving credit facility. The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close in the second half of 2022. The company intends to provide detailed forward-looking guidance for the remainder of 2022 at or shortly after closing of the transaction. Upon closing, Sean Smith will serve as Executive Chair of the Board of Directors of the newly combined business, and Will Hickey and James Walter will lead the company as Co-CEOs and will serve on the Board of Directors. Matt Garrison, Centennial's current Chief Operating Officer, and George Glyphis, Centennial's current Chief Financial Officer, will continue to serve in their respective roles at the combined company. The combined company will be headquartered in Midland, with key positions filled by representatives from both companies. The Denver office will remain open for the foreseeable future to ensure continuity and continued operational success. The combined company will operate under a new name and stock ticker symbol, which are expected to be announced prior to closing. Following the merger, Centennial's Board of Directors will be expanded to eleven directors, consisting of Sean Smith, Will Hickey, James Walter, William Quinn and Robert Tichio, in addition to six independent directors. Immediately following the closing, existing Centennial shareholders will own approximately 53% of the combined company, and existing Colgate owners will own approximately 47% of the combined company. Centennial's largest shareholder, Riverstone, which currently owns approximately 25% of Centennial's outstanding shares, has executed a Voting and Support Agreement in connection with the transaction. The closing of the merger is subject to customary closing conditions, including approval by Centennial shareholders and regulatory approvals.

07:09 EDT Bragg Gaming approved for license by Pennsylvania Gaming Control Board - Bragg Gaming announced that at yesterday's meeting, the Pennsylvania Gaming Control Board, or PGCB, approved the company to participate in the Commonwealth's iGaming market. The PGCB's approval is the final regulatory approval needed in advance of closing for Bragg to complete its previously announced acquisition of Spin Games which the company expects to close later this month. Nevada-based Spin Games is a B2B gaming technology and content provider currently servicing the U.S. market. Spin Games holds licenses in iGaming-regulated U.S. states including New Jersey, Pennsylvania, Michigan and Connecticut, and supplies Tier 1 operators in these markets.

07:08 EDT Children's Place to close 40 stores this year - The Company ended the first quarter of 2022 with 665 stores and square footage of 3.2 million, a decrease of 8% compared to the prior year and a decrease of 30% compared to the end of Q1 2019 when the Company operated 971 stores pre-pandemic. Consistent with the Company's store fleet optimization initiative, the Company permanently closed 7 stores during the first quarter of 2022 and has permanently closed 534 stores since 2013 and decreased total square footage by 2.1 million square feet or approximately 40%. The Company is planning to close a total of approximately 40 stores this year.

07:07 EDT Kohl's provides update on review of potential alternatives - The company said, "The Kohl's Board is thoroughly testing the Company's standalone strategic plan against potential alternatives and has designated its Finance Committee to lead the ongoing review of expressions of interest. The Board engaged Goldman Sachs to conduct a broad process to explore strategic alternatives, which to date has included engagement with over 25 parties. Multiple bidders have been invited to a data room containing over 550,000 pages across over 55,000 documents, as well as meetings with management. While preliminary, non-binding proposals have been received, further diligence is ongoing and the Board has requested fully-financed final bids to be submitted in the coming weeks."

07:05 EDT Alpine Acquisition enters agreements to acquire Two Bit Circus, two hotels - Alpine Acquisition Corporation and Two Bit Circus announced that they have entered into definitive agreements for a business combination. Alpine also entered into a definitive agreement with affiliates of Atrium Hospitality, LP, to acquire two full-service conference hotels with 739 rooms and 135,000 square feet of conference facilities located in Denver, CO and Stamford, CT. Upon the closing of the transactions, Alpine will acquire Two Bit Circus and the hotels and commence transformational renovations of both properties. The properties will be rebranded to Revelers Resorts, using Two Bit Circus's proprietary technology and entertainment experiences. The combined company is expected to be renamed "Two Bit Entertainment Corp." and continue to be listed on NASDAQ under the symbol REVE. The transactions are expected to close in the 3rd quarter of 2022. The new entertainment brand, Revelers Resorts, will provide inclusive activities along with an immersive story experience woven throughout the entire resort; Circus adventures, STEAM games and workshop activities bring to life the Reveler's world. Full food and beverage offerings are expected to include Plate Spinner Pizza and a Cannonball Candy Shop along with carnival carts with signature treats. Revelers Resort will also have one of a kind social play attractions and other games, such as a reimagined arcade and midway for upleveled play throughout Reveler's Circus Grounds area. Purchasing existing conference center hotels in strong demographic locations at deep discounts to their replacement costs is expected to allow the new brand to quickly enter new markets, provide affordable entertainment and lodging accommodations, and grow quickly and profitably. These hotels already have the full-service amenities needed to adapt and renovate to the new brand along with leveraging the Two Bit Circus' immersive-fueled experiential entertainment technology to create Revelers Resorts. Two Bit Circus shareholders will contribute 100% of their equity into the combined company. Alpine will issue an aggregate of 4,980,000 shares of common stock to the Two Bit Circus shareholders and 1,950,000 shares of common stock to the sellers of the hotels being acquired. The boards of directors of Alpine and Two Bit Circus have approved the proposed business combination. Completion of the proposed business combination is subject to approval by Alpine's stockholders and the satisfaction or waiver of other customary closing conditions. $50 million all stock transaction from Alpine Acquisition Corporation for Two Bit Circus, Inc.; $65 million cash and stock purchase of two full-service conference hotels with 739 rooms and over 140,000 square feet of conference facilities located in Denver, CO and Stamford, CT; Transactions expected to close in the third quarter of 2022.

07:03 EDT Wex, AutoZone enter partnership - WEX announced a partnership with AutoZone. This partnership will allow eligible WEX customers to purchase auto parts for Class 1-5 vehicles from AutoZone at national account pricing through the WEX EDGE savings network. WEX EDGE offers eligible WEX fleet card customers access to highly specialized offers including fuel rebates, discounted tires, and hotel rooms. The addition of auto parts allows these WEX customers to share even further in the savings. The discounts apply to auto parts purchased through the WEX EDGE platform.

07:01 EDT Advanced Drainage raises quarterly dividend 9% to 12c per share - Advanced Drainage Systems announced that its Board of Directors has approved a quarterly cash dividend to its shareholders in the amount of $0.12 per share, a 9% increase over the prior year dividend amount. The quarterly cash dividend of $0.12 per share will be paid on June 15, 2022, to shareholders of record at the close of business on June 1, 2022.

06:52 EDT Spirit Airlines urges stockholders to reject JetBlue tender offer - Spirit Airlines (SAVE) announced that its board of directors, after consultation with its outside financial and legal advisors, has unanimously determined that the unsolicited tender offer from JetBlue (JBLU) to acquire all outstanding shares of Spirit's common stock for $30 per share in cash is not in the best interests of Spirit and its stockholders. In its analysis, the board determined that the JetBlue transaction faces substantial regulatory hurdles, especially while the Northeast Alliance, or NEA, with American Airlines (AAL) remains in effect, and is, as a result, not reasonably capable of being consummated and is not superior to Spirit's agreed merger transaction with Frontier (ULCC). Accordingly, the Spirit Board unanimously recommends that Spirit stockholders not tender any of their shares into the offer and continues to recommend that stockholders vote for the merger agreement with Frontier. "JetBlue's tender offer has not addressed the core issue of the significant completion risk and insufficient protections for Spirit stockholders," said Mac Gardner, chairman of the board of directors for Spirit Airlines. "Based on our own research and the advice of antitrust and economic experts, our view is that the proposed combination of JetBlue and Spirit lacks any realistic likelihood of obtaining regulatory approval, while our company faces a long and bleak limbo period as we await resolution. In that scenario, a $1.83 per share reverse break-up fee will not come close to adequately compensating Spirit stockholders for the significant business disruption Spirit will face during what JetBlue acknowledges will be a protracted regulatory process. Our pending merger with Frontier is advancing as planned, and we continue to recommend that Spirit stockholders vote for the merger with Frontier on June 10th, as we believe the combination of these two ULCCs is the best way to deliver maximum value to Spirit stockholders."

06:38 EDT Teleflex announces regulatory clearance for UroLift System in China - Teleflex announced that it has received National Medical Products Administration approval for its UroLift System in China for treating benign prostatic hyperplasia. With regulatory clearance now received, Teleflex will seek commercialization of the product in China in the fourth quarter of 2022.

06:33 EDT Eagle Materials board authorizes repurchase of additional 7.5M shares - Eagle's Board of Directors has authorized the repurchase of an additional 7.5 million shares of its common stock. This increase is in addition to the remaining authorized shares under the existing share repurchase authorization. The total new authorization plus remaining authorization is approximately 10.3 million shares and represents nearly 25% of Company shares outstanding. Share repurchases may be made from time to time in the open market or in privately negotiated transactions, which may include executing any or all of self-tender offers, entering into accelerated share repurchase programs with financial institutions, and making open market purchases and block trades, including plans intended to comply with the safe-harbor provided by Rule 10b5-1. Funding for such share repurchases will come from internally generated cash flow or from existing or new credit facilities.

06:33 EDT PNM Resources promotes Don Tarry to COO, Lisa Eden to CFO - PNM Resources announced the promotion of two executives as part of the company's ongoing development efforts under the continued leadership of chairman and CEO, Pat Vincent-Collawn. Don Tarry has been promoted to president and COO of PNM Resources. Tarry joined PNM Resources in 1996 and has most recently served as senior VP and CFO. Lisa Eden has been promoted to senior VP, CFO and treasurer. Eden joined PNM Resources in 2001 and has previously served as VP and treasurer; chief information officer and VP, Human Resources.

06:27 EDT Bath & Body Works sees FY inflation impact $225M-$250M - The company says it is strategically raising prices and carefully managing promotional activity to maximize margin dollars. The company also says it will accelerate the rollout of its customer loyalty program to August. The accounting impact of the rollout of the program is expected to result in an estimated $50M initial revenue deferral this year.

06:24 EDT Bath & Body Works: Overall Q1 transactions up low single digits vs. last year - Comments taken from Q1 earnings conference call presentation slides and commentary.

06:19 EDT Voyager Therapeutics to present preclinical data on TRACER capsids - Voyager Therapeutics is scheduled to present new preclinical data on a family of AAV9-derived TRACER capsids demonstrating cross-species central nervous system transduction. The Company is also scheduled to report updated results from preclinical gene therapy programs in GBA1, tauopathies, and SOD1 ALS. These results are being presented at the American Society of Gene and Cell Therapy 25th Annual Meeting in Washington, D.C. Family of AAV9-Derived Capsids Enhanced Brain Transduction Across Non-Human Primates and Mice: Voyager's TRACER capsid discovery platform has identified a novel AAV9-derived capsid, VCAP-102, which demonstrated 50-fold better transduction in mice and 60-fold better transduction in non-human primates versus conventional AAV9 capsids, following intravenous administration. While other TRACER capsids have shown strong neuronal delivery, preclinical data in this study also demonstrated that VCAP-102 and other TRACER capsids showed preferential tropism for glial cells in mice. Key Results: Top variants from the capsid family exhibited increased blood brain barrier-penetrance across NHP species and mice. Top variants showed preferential transduction of glial cells in mice. Certain variants displayed significant detargeting from peripheral organs, including the dorsal root ganglia and liver. Additional results are scheduled to be presented today at the ASGCT Annual Meeting at 11:00 a.m. ET in Ballroom A at the Washington, D.C. Convention Center. The Company intends to make full results available on the Investor page of the Voyager website following the conclusion of the oral presentation. GBA1, Tau, and SOD1 ALS Gene Therapy Programs Ameliorate Disease in Animal Models: Voyager is scheduled to present preclinical data demonstrating improvements in physiologic parameters across pipeline programs involving CNS targets of interest: GBA1, tauopathies, and SOD1 ALS. Key Results: Multiple transgenes for the optimal expression of glucocerebrosidase 1, the gene encoding the lysosomal enzyme glucoslyceramidase, were characterized in both in vitro and in vivo mouse models. GBA1 transgenes using a BBB-penetrant AAV capsid delivered therapeutically-relevant levels of GCase to multiple brain regions in mouse models, following a single IV dose. The Company intends to make full results available on the Investor page of the Voyager website. Tauopathies: Key Results: Systemic dosing of a vectorized anti-tau antibody in mouse models resulted in reduced tau pathology and may represent a new single-dose IV therapeutic strategy for various tauopathies. The antibody demonstrated robust efficacy in vectorized and passive forms in a hippocampal seeding mouse model of Alzheimer's Disease. Treatment with vTau resulted in significant reduction of tau pathology in CNS regions of a primary tauopathy mouse model. When delivered passively, the antibody exhibited a trend of reduction in tau pathology in CNS regions of an intrinsic mouse model. The Company intends to make full results available on the Investor page of the Voyager website. SOD1 ALS: Key Results: IV delivery of a BBB-penetrant AAV9-derived capsid containing superoxide dismutase 1a-targeting RNAi gene therapy dramatically improved motor performance and survival in a SOD1- amyotrophic lateral sclerosis mouse model. Robust knockdown of SOD1 in all levels of the spinal cord was observed in a SOD1-ALS mouse model. Data support preclinical development of an IV RNAi gene therapy using a novel BBB-penetrant capsid in primates.

06:13 EDT Digihost announces launch of 1.22M share buyback program - Digihost Technology is pleased to announce that it has received approval to undertake, at the Company's discretion, a normal course issuer bid program to purchase up to 1,219,762 of its subordinate voting shares for cancellation. As of the date hereof, the Company has 27,685,913 subordinate voting shares issued and outstanding. The maximum number of subordinate voting shares that may be purchased by the Company under the Bid represents approximately 5% of the Company's currently issued and outstanding shares. Shares repurchased under the Bid will be returned to treasury for cancellation. The Company received acceptance from the TSX Venture Exchange to commence the Bid on May 25, 2022. The Bid will terminate on May 25, 2023, or on an earlier date in the event that the maximum number of common shares sought in the Bid has been repurchased. The Company reserves the right to terminate the Bid at any time. Purchases pursuant to the Bid are expected to be made through the facilities of the TSXV, or such other permitted means, at prevailing market prices. The Company has engaged Canaccord Genuity Corp. to act as the broker through which the Bid will be conducted. The Company purchased a total of 164,533 post-consolidation subordinate voting shares during the past 12 months subject to its previous normal course issuer bid at an average purchase price of CAD $4.60 per subordinate voting share. The subordinate voting shares were acquired through the facilities of the TSXV by Canaccord Genuity Corp. The Company completed its most recent financing on March 6, 2022, at CAD $4.40 per unit.

06:08 EDT Krispy Kreme celebrates Class of 2022 with free Senior Day Dozen - Krispy Kreme is celebrating this year's high school and college seniors - and their dedication and perseverance throughout the pandemic - with a FREE dozen doughnuts May 25 and the return of the Graduate Dozen, available beginning May 23. On Wednesday, May 25, any senior who wears Class of 2022 swag - from shirts and jackets to graduation cap and gown - can get a "Senior Day Dozen" FREE at participating shops while supplies last.

06:06 EDT Curo Group to sell Legacy U.S. Direct Lending Business, acquire First Heritage - CURO Group Holdings entered into a definitive agreement to sell its Legacy U.S. Direct Lending business to Community Choice Financial, a consumer financial services company based in Dublin, Ohio, for total cash consideration of $345M, $35M of which will be payable over 12 months under a Transition Services Agreement. CURO also has entered into a definitive agreement to acquire First Heritage Credit, a consumer lender that provides near-prime installment loans along with customary opt-in insurance and other financial products, based in Ridgeland, Mississippi. The total purchase price is $140M in cash. "In late 2021, we acquired Heights Finance, a leading near-prime installment lender, signifying our entry into this broader consumer lending market in the U.S.," said Don Gayhardt, Chief Executive Officer of CURO. "Continuing on that strategic shift, today we are announcing that we are selling our legacy storefronts and online businesses in the U.S., which operate under the Speedy Cash, Rapid Cash and Avio Credit brands, and we are purchasing a U.S. based near-prime installment lender, First Heritage Credit. Together, these transactions completely transform our U.S. direct lending business to a near-prime installment lender offering larger loans. These three transactions have strategically recast our U.S. direct lending business in less than a year's time." The transactions have been approved by CURO's Board of Directors and the Board of Directors of Community Choice Financial and First Heritage Credit, respectively. Both transactions are expected to close within the next 45 days, subject to customary closing conditions, including regulatory approvals.

05:23 EDT MasterCard, OPay enter strategic partnership - OPay and Mastercard announced a strategic partnership, which marks a significant boost for wider financial inclusion and economic prosperity by opening up digital commerce to millions of people across Middle East and Africa. The collaboration enables OPay consumers and merchants in the region - including Algeria, Morocco, Egypt, Nigeria, Ethiopia, Kenya, Pakistan, South Africa and the UAE - to engage with brands and businesses anywhere across the globe, thanks to a Mastercard virtual payment solution linked to the OPay eWallet. In the initial phase of this partnership, OPay customers will benefit from the Mastercard virtual payment solution linked to their OPay wallets, to shop at well-known global brands for leisure, travel, accommodation, entertainment, streaming services and more. The service is available regardless of whether or not the customer has a bank account. It also allows small business owners to purchase from suppliers abroad and pay with the secure virtual payment solution.

05:15 EDT Jacobs selected by TEPCO to decommission Fukushima Daiichi nuclear power plant - Jacobs was selected by Tokyo Electric Power Company, or TEPCO, to support decommissioning of the Fukushima Daiichi nuclear power plant in Japan. Under a five-year framework agreement, Jacobs will draw on domain knowledge and experience on major U.S. and U.K. nuclear sites to provide program and project management services to TEPCO's Fukushima Decontamination and Decommissioning Engineering Company. Jacobs' involvement will include project management support, long-term decommissioning strategy planning, management and implementation of supply chain resources and program definition for fuel debris retrieval.